Drug, bio-affecting and body treating compositions inventions 12/07

20070299017 - Compositions for lowering blood serum cholesterol and use in foods, beverages, and health supplements: There is disclosed a composition comprising at least one of a compound selected from the group consisting of a bioflavonoid, a beta-1,3-beta-1,4-polymer of glucose having a weight average molecular weight (MW) of not greater than 1000 kDa, and a sterol. Moreover, there is disclosed a food or beverage or health... Agent: Cargill, Incorporated

20070298998 - Biomarkers for amyotrophic lateral sclerosis and methods using the same: The present invention provides various biomarkers of amyotrophic lateral sclerosis (ALS). The present invention also provides various methods of using the biomarkers, including methods for diagnosis of ALS, methods of determining predisposition to ALS, methods of monitoring progression/regression of ALS, methods of assessing efficacy of compositions for treating ALS, methods... Agent: Hutchison Law Group PLLC

20070298997 - Compounds useful in treating diabetic microvascular complications and age-related macular degeneration: The present invention is directed to a method of treating microvascular complications associated with diabetes and age-related macular degeneration. The methods include administering to an animal in need thereof an effective amount of a composition, wherein the composition is selected from the group consisting of kallistatin, fragments of kallistatin, analogs... Agent: Dunlap Codding & Rogers, P.C.

20070298999 - Method for treating pain with a calmodulin inhibitor: The present invention relates to the use of Ca2+/CaM-dependent protein kinase II (CaMKII) inhibitors alone and in combination with opiate analgesics for treating pain, in particular chronic pain. Methods for reducing or reversing tolerance and dependence on opiate analgesics are also provides.... Agent: Jane Massey Licata Licata & Tyrrell P.C.

20070299000 - Method of lowering body fat percentage or inhibiting body fat percentage increase: A body fat percentage-lowering agent or an inhibitor for an increase in body fat percentage containing soybean 7S protein as the active ingredient and foods containing the same. As the soybean protein 7S protein, use is made of a protein the purity of which is elevated by sufficiently separating from... Agent: Wenderoth, Lind & Ponack, L.L.P.

20070298996 - Methods of using chimeric coiled-coil molecule: The present application discloses a method of treating a disease that is treatable by therapeutic angiogenesis comprising administering to a needy subject an effective amount of a chimeric coiled coil molecule comprising a coiled-coil domain linked to a receptor binding domain of a ligand.... Agent: Jhk Law

20070299001 - Purified hcg: A process for the purification of recombinant human Chorionic Gonadotropin (hCG) from a sample of crude recombinant hCG in the supernatant of CHO cells comprises the combined use of ion-exchange chromatography and reverse phase HPLC. The ion-exchange chromatography is performed twice and the final use of a size exclusion chromatography... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20070299002 - Alpha1-acid glycoprotein for the treatment of diabetes: Methods of using alpha-1-acid glycoprotein, or an active derivative, to modulate the blood glucose level in mammals, particularly humans, is described. A therapeutically effective amount of alpha-1-acid glycoprotein is administered to a patient afflicted with Type 1 or Type 2 diabetes to lower the blood glucose level. An anti-diabetic medicament,... Agent: Faegre & Benson LLP Patent Docketing

20070299003 - Composition comprising a pulmonary surfactant and a tnf-derived peptide: The invention relates to the combination of a pulmonary surfactant and a TNF-derived peptide and its use for the treatment of respiratory disease.... Agent: Nath & Associates PLLC

20070299004 - Methods of providing therapeutic effects using cyclosporin compontnts: Methods of treating an eye of a human or animal include administering to an eye of a human or animal a composition in the form of an emulsion including water, a hydrophobic component and a cyclosporin component in a therapeutically effective amount of less than 0.1% by weight of the... Agent: Stout, Uxa, Buyan & Mullins LLP

20070299009 - Analogs of parathyroid hormone: The present invention is directed to peptide analogues of fragment of parathyroid hormone (PTH) or parathyroid hormone-related protein (PTHrP), a method of using said analogues alone or in combination with a bisphosphonate or calcitonin to treat osteoporosis and pharmaceutical compositions comprising said analogues alone or in combination with a bisphosphonate... Agent: Biomeasure, Incorporated

20070299011 - Appoptosin and uses thereof for treating neurodegenerative disease and cancer: Disclosed herein are compositions and methods relating to the modulation of Appoptosin levels or activity in the treatment of Neurodegenerative disorders or cancer.... Agent: Needle & Rosenberg, P.C.

20070299010 - Cpg15 and cpg15-2 compounds and inhibitors as insulin receptor and insulin-like growth factor receptor agonists and antagonists: Disclosed herein are CPG15 and CPG15-2 compounds and inhibitors that act as agonists and antagonists of the insulin receptor and insulin-like growth factor receptors, and the use of such compositions for the treatment of insulin and insulin-like growth factor-related diseases.... Agent: Clark & Elbing LLP

20070299005 - Family of genes encoding apoptosis-related peptides, peptides encoded thereby and methods of use thereof: An isolated polynucleotide at least 60% homologous to SEQ ID NO: 1, 3, 5 or 18 encoding a SARP polypeptide; vectors comprising a polynucleotide sequence encoding at least 11 consecutive amino acids of αSARP polypeptide; a host cell transformed with an isolated polynucleotide or vector; antibodies specific for SARP and... Agent: Sheridan Ross PC

20070299007 - Muteins of fibroblast growth factor 21: The present invention relates to novel muteins of human fibroblast growth factor-21 with reduced susceptibility for proteolytic degradation when expressed in yeast. Both protein and the respective encoding nucleic acid species are disclosed. The invention also embodies vectors and host cells for the propagation of said nucleic acid sequences and... Agent: Eli Lilly & Company

20070299006 - Recombinant fusion proteins to growth hormone and serum albumin: The invention describes albumin fusion proteins comprising growth hormone and serum albumin. The invention also describes nucleic acid molecules encoding the albumin fusion proteins of the invention, as well as vectors containing these nucleic acid molecules, host cells transformed with these vectors, and methods of making the albumin fusion proteins... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070299008 - Transport protein which is used to introduce chemical compounds into nerve cells: The invention relates to a transport protein which can be obtained by modifying the heavy chain of the neurotoxin formed by Clostridium botulinum. The protein binds specifically to nerve cells with a higher affinity as the native neurotoxin. The invention also relates to a method for the production of transport... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20070299012 - Method of preventing progression of hypertension-induced heart failure with pkc peptides: Methods are described for slowing or inhibiting the progression of heart failure in a mammalian subject suffering from chronic hypertension. The methods involve administering an εPKC, β1PKC, or βIIPKC peptide inhibitor, examples of which are provided.... Agent: Perkins Coie LLP

20070299013 - Exosite-directed thrombin inhibitors: Disclosed are an amino acid sequence of the human blood clotting factor Va, peptides containing such sequence, and additional peptides of interest that significantly inhibit thrombin generation. Also disclosed are pharmaceutical compositions containing these peptides and related therapeutic methods for inhibiting thrombin generation and treating blood coagulation disorders.... Agent: Mark E Bandy Fay Sharpe Fagan Minnich & Mckee LLP

20070299014 - Casein hydrolyzate, process for producing the same and use thereof: The present invention relates to a casein hydrolysate containing free amino acids and in vivo indigestible peptides having minimally suppressed in vivo enzymatic digestibility, and expected to express functions, such as hypotensive effect, in living organism, and to a method for preparing such a hydrolysate, and use thereof. The casein... Agent: Darby & Darby P.C.

20070299015 - Peptide fragments for inducing synthesis of extracellular matrix proteins: Short biologically active tetrapeptides are disclosed that are comprised of the sequences GxxG and PxxP where G (glycine) and P (proline) are maintained and x is a variable amino acid. The peptides can be used singly or in combination to stimulate production of extracellular matrix proteins in skin. A rapid,... Agent: Howrey LLP

20070299016 - Specific antibodies for diagnosing heart failure: The invention relates to an in vitro diagnosis of heart failure. More specifically, the invention relates to specific antibodies of a peptide domain which is situated on either side of hinge region R76S77 of proBNP(1-108). In particular, the invention relates to a method of obtaining the aforementioned antibodies and to... Agent: Jacobson Holman PLLC

20070299018 - Derivatives of genkwanin and sakuranetin, cosmetic and therapeutic use thereof and preparation method of same: The invention relates to: (i) the use of osyl derivatives of genkwanin and sakuranetin having formula (I) in (a) cosmetics or dermatology and (b) therapeutics; (ii) the use of novel derivatives having formula (I) as industrial products; and (iii) the production method thereof [Formula (I)], wherein symbol [Formula (II)] represents... Agent: Ostrolenk Faber Gerb & Soffen

20070299019 - Macrolides and methods for producing same: This invention relates, in part, to macrolide compounds, actinomycete strains for producing them, and pharmaceutical compositions containing them.... Agent: Howson And Howson/wyeth Cathy A. Kodroff

20070299020 - Methods for treatment of ovarian, colorectal or pancreatic cancer using 4-(aminno)-2(2,6-dioxo(3-piperidyl)-isoindoline-1,3-dione: Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active ingredient. The invention further relates to methods of reducing or... Agent: Jones Day

20070299022 - Antisense oligonucleotide to inhibit melanoma inhibitory activity mia: An antisense oligonucleotide selected from the group of the sequence 5′-TTG CAT AAA CCC AAG GAG-3′ and modifications thereof a fragment having at least 8 nucleotides of the sequence 5′-TTG CAT AAA CCC AAG GAG-3′ and modifications thereof.... Agent: Wood, Herron & Evans, LLP

20070299028 - Backbone modifications to modulate oligonucleotide targeting in vivo: The present invention provides antisense compounds and methods for modulating the expression of target genes expressed in the kidney. In particular, this invention provides antisense oligonucleotide compounds optimized for targeting nucleic acid molecules expressed in the kidney. Such compounds are shown herein to efficiently modulate the expression of target genes... Agent: Mcdermott Will & Emery

20070299024 - Cloning and characterization of 5'flanking regions of a human aggrecanase-1 gene: Disclosed is a nucleic acid comprising Agg promoters and methods of using the same. The invention also provides methods for identifying and treating disease based on the activity of Agg promoters.... Agent: Novartis Corporate Intellectual Property

20070299027 - Compositions and their uses directed to huntingtin: Disclosed herein are compounds, compositions and methods for modulating the expression of huntingtin in a cell, tissue or animal. Further provided are methods of slowing or preventing Huntington's disease progression using an antisense compound targeted to huntingtin. Additionally provided are methods of delaying or preventing the onset of Huntingtin's disease... Agent: Knobbe, Martens, Olson & Bear, LLP

20070299029 - Hepatic stellate cell specific promoter and uses thereof: Methods and reagents for effecting transgene expression in a hepatic stellate cell, isolated transgenic hepatic stellate cells, methods and reagents for identifying compounds with fibrogenesis modulating properties and uses thereof.... Agent: Klarquist Sparkman, LLP

20070299026 - Immunosuppressive cytokine: The EB1-3-p35 cytokine is shown for the first time to be capable of inhibiting immune responses mediated or controlled by T cells via an effect on suppressor T cells. This suggests that EBI3-p35 may be therapeutically effective in a variety of inflammatory and autoimmune conditions including arthritis, atherosclerosis, allograft rejection,... Agent: Dann, Dorfman, Herrell & Skillman

20070299025 - Method for detecting the risk of cardiovascular diseases such as acute myocardial infarction and coronary heart disease by analysing defesin: The invention provides a method of identifying subject's susceptibility or predisposition to or risk of developing cardiovascular diseases such as myocardial infarction (MI) or coronary heart disease (CHD) by detecting gene polymorphisms and other gene mutations in a defensin gene from a biological sample of the subject and obtaining information... Agent: Birch Stewart Kolasch & Birch

20070299030 - Microrna biomarkers for human breast and lung cancer: The present invention relates to novel molecular markers for diagnosis and classification of human breast cancer and lung cancer.... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20070299021 - Modified tailed oligonucleotides: A nucleic acid molecule comprising first and second domains, said first domain being capable of forming a first specific binding pair with a target sequence of a target RNA species, said second domain consisting of a sequence which forms a second specific binding pair with at least one RNA processing... Agent: Jaeckle Fleischmann & Mugel, LLP

20070299023 - P185neu-encoding dna and therapeutical uses thereof: Plasmids containing sequences encoding different fragments of p185neu oncoprotein, able to induce an immune response against tumours expressing oncogenes of the ErbB family, and pharmaceutical compositions thereof.... Agent: Young & Thompson

20070299031 - Therapeutic agent for tumor of neural origin: The present invention is directed to a therapeutic agent for a tumor of neural origin, containing, as an active ingredient, any of the following: Hu protein; a polypeptide having an amino acid sequence derived from an amino acid sequence of Hu protein by substitution, deletion, addition, or insertion of one... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20070299032 - Method and composition for thickening hair: The present invention provides a method for maintaining and promoting hair thickening by increasing the expression of keratinocyte growth factor (FGF-7) in hair follicle cells, and preferably dermal papilla cells, a composition for increasing expression of FGF-7 that contains adenosine and/or a derivative thereof, and particularly, an external scalp preparation... Agent: Snider & Associates

20070299033 - Pharmaceutical co-crystal compositions and related methods of use: The present invention comprises pharmaceutical compositions comprising a co-crystal of an API and a co-crystal former, and methods of making and using the same.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20070299034 - Cell wall derivatives, their preparation process, and use thereof: In a first aspect, the present invention relates to a method for isolating cell wall derivatives from fungal or yeast biomass. According to this method, chitin polymers or chitin-glucan copolymers can be obtained. In another aspect, the invention relates to a method for preparing chitosan from chitin. The invention further... Agent: Clark & Brody

20070299035 - Use of chemical chelators as reversal agents for drug-induced neuromuscular block:

20070299036 - Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-iv: The present invention is directed to a method of treatment of a malcondition that can be regulated or normalized via inhibition of DPP-IV. The method involves administration of an effective amount of a pyrrolidine compound of the invention, such as would be present in a pharmaceutical composition of the invention,... Agent: Schwegman, Lundberg & Woessner, P.A.

20070299037 - Synergistic and residual pesticidal compositions containing plant essential oils: Synergistic and residual pesticidal compositions containing synergistic and residual mixtures of plant essential oils and/or their constituents, plant essential oils and/or their constituents in admixture with known active pesticidal compounds or plant essential oils and/or their constituents in admixture with other compounds not previously used as active ingredients in pesticidal... Agent: Nixon & Vanderhye, PC

20070299038 - Synergistic and residual pesticidal compositions containing plant essential oils: Synergistic and residual pesticidal compositions containing synergistic and residual mixtures of plant essential oils and/or their constituents, plant essential oils and/or their constituents in admixture with known active pesticidal compounds or plant essential oils and/or their constituents in admixture with other compounds not previously used as active ingredients in pesticidal... Agent: Nixon & Vanderhye, PC

20070299039 - Substituted benz-azoles and methods of their use as inhibitors of raf kinase: New substituted benz-azole compounds, compositions and methods of inhibition of Raf kinase activity in a human or animal subject are provided. The new compounds compositions may be used either alone or in combination with at least one additional agent for the treatment of a Raf kinase mediated disorder, such as... Agent: Chiron Corporation Intellectual Property - R440

20070299040 - Composition for preventing a cold: The present invention relates a composition for preventing cold comprising vitamin C and ginkgetin, a use of the composition for preparing a medicine To prevent cold, a method for preventing cold by using the composition, and method for preparing cold prophylactic. The composition of the present invention has excellent inhibition... Agent: Ipla P.A.

20070299041 - Induction of innate immunity by vitamin d3 and its analogs: Cationic antimicrobial peptides (AMPs) are an integral part of the innate immune system. Cathelicidin and defensin homologs from a variety of species exhibit broad-range bactericidal activity. The human cathelicidin analog, hCAP18, is encoded by the CAMP gene. Vitamin D3 and its analogs upregulate transcription of CAMP and defensin B2 (defB2)... Agent: Davis Wright Tremaine LLP/los Angeles

20070299043 - Anti-scarring drug combinations and use thereof: The present invention provides devices or implants that comprise anti-scarring drug combinations, methods or making such devices or implants, and methods of inhibiting fibrosis between the devices or implants and tissue surrounding the devices or implants. The present invention also provides compositions that comprise anti-fibrotic drug combinations, and their uses... Agent: Clark & Elbing LLP

20070299042 - Use of etodolac to treat hyperplasia: wherein R1 is lower alkyl, (hydroxy)lower alkyl, lower alkenyl, lower alkynyl, lower cycloalkyl, phenyl, benzyl or 2-thienyl; R2, R3, R4 and R5 are the same or different and are each hydrogen or lower alkyl; each R6 is individually hydrogen, lower alkyl, hydroxy, (hydroxy)lower alkyl, lower alkoxy, benzyloxy, lower alkanoyloxy, nitro... Agent: Schwegman, Lundberg & Woessner, P.A.

20070299044 - Corticosteroid topical dispersion with low content of surfactant: The invention provides novel compositions of water-insoluble corticosteroid drug in combination with antimicrobial agents and very low concentrations of polymers and surfactants for topical, otic and ophthalmic treatment. The invention provides stable aqueous suspension where the ingredients remain in such a state so as to allow for immediate re-suspension, when... Agent: Lerner, David, Littenberg, Krumholz & Mentlik

20070299045 - Anti-viral composition for the topical treatment of herpes labialis (cold sores) and method for use thereof: A composition for the treatment of Herpes Labialis which contains CTC-96 as the active ingredient is disclosed. Methods for using the composition are also disclosed. The composition may be used as a topical ointment.... Agent: Reed Smith, LLP Attn: Patent Records Department

20070299046 - Orally available light-independent antineoplastic compounds: Pheophorbide derivative compounds which can inhibit cell proliferation and angiogenesis in a light-independent manner are disclosed and claimed. Importantly, these compounds exhibit low toxicity, and are orally/subcutaneous/intravenously/transdermally/topically available, thus having value as new potential agents to treat cancer or diseases related to imbalance in cell proliferation and angiogenesis.... Agent: Craig A. Crandall, Apc

20070299047 - Combination of organic compounds: The present invention relates to a pharmaceutical composition, comprising a PPAR agonist, or pharmaceutically acceptable salts thereof, alone or in combination with at least one active ingredient selected from the group consisting of (i) HDL increasing compounds; (ii) anti-diabetics; (iii) an anti-hypertensive agent; (iv) cholesterol absorption modulator; (v) apo-A1 analogs... Agent: Novartis Corporate Intellectual Property

20070299048 - Combination of gaboxadol and 5ht2 antagonists: The invention provides the combination of a 5-HT2A antagonist and gaboxadol for use in treatment or prevention of sleep disorders, schizophrenia or depression.... Agent: Merck And Co., Inc

20070299049 - Pharmaceutical uses of staurosporine derivatives: This application relates to the use of staurosporines derivatives for the curative, palliative or prophylactic treatment of allergic rhinitis, allergic dermatitis, drug allergy or food allergy, angioedema, urticaria, sudden infant death syndrome, bronchopulmonary aspergillosis, multiple sclerosis, or mastocytosis; and to a method of treatment of warm-blooded animals in which a... Agent: Novartis Corporate Intellectual Property

20070299050 - Fused tricyclic compounds as inhibitors of tumor necrosis factor-alpha: are disclosed, wherein V is CH2; W is S(O)m; m is the integer 0, 1 or 2; U is O, C(O), CR13R14 or NR15; where R13 is H, alkyl; R14 is H, OH, OR13 or OCOR13; R15 is H, alkyl, cycloalkyl, alkenyl, C(O)R13, C(O)OR13 or alkylaminocarbonyl; R1, R2, R3, R4,... Agent: Merchant & Gould PC

20070299051 - Tricyclic guanidine derivatives as sodium-proton exchange inhibitors: are disclosed, wherein U is C(O), CRaRb, O, NRa or S(O)m; V is CRaRb or NRa; W is S(O)m; wherein Ra is H, alkyl, cycloalkyl, alkenyl or aralkyl; Rb is H, alkyl, OH, ORa or OCORa, and m is the integer 0, 1 or 2; R1, R2, R3, R4, R5,... Agent: Merchant & Gould PC

20070299052 - Inhibitors of iap: e

20070299054 - Oral pharmaceutical composition of a poorly water-soluble active agent: The present invention relates to an improved oral pharmaceutical composition containing at least one poorly water soluble active agent, the active agent containing at least one of an endothelin conversion enzyme (ECE) inhibitor and a neutral endopeptidase (NEP) inhibitor in an amount greater than 10% w/w of the composition, and... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070299053 - Lactam compound: The present invention provides crystalline (N)-((S)-2-hydroxy-3-methyl-butyryl)-1-(L-alaninyl)-(S)-1-amino-3-methyl-2,3,4,5-tetrahydro-1H-3-benzazepin-2-one, a crystalline anydrate and dihydrates thereof, compositions comprising (N)-((S)-2-hydroxy-3-methyl-butyryl)-1-(L-alaninyl)-(S)-1-amino-3-methyl-2,3,4,5-tetrahydro-1H-3-benzazepin-2-one, its crystalline anhydrate or dihydrate, and methods for using the same.... Agent: Eli Lilly & Company

20070299055 - Combination of sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression: One aspect of the present invention relates to pharmaceutical compositions containing two or more active agents that when taken together can be used to treat, e.g., insomnia and/or depression. The first component of the pharmaceutical composition is a GABA receptor modulating compound. The second component of the pharmaceutical composition is... Agent: Heslin Rothenberg Farley & Mesiti P.C.

20070299056 - Benzazepine derivatives for the treatment of neurological disorders: The present invention relates to benzazepine derivatives of formula (I) wherein: R1 represents —C3-7 cycloalkyl optionally substituted by C1-3 alkyl; having pharmacological activity, processes for their preparation, to compositions containing them and to their use in the treatment of neurological and psychiatric disorders.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B475

20070299057 - Heterocyclic piperidines as modulators of chemokine receptor activity: e

20070299058 - Anxiolytic agents with reduced sedative and ataxic effects: Orally active benzodiazepine derivatives and their salts are disclosed. These compounds and their salts have anxiolytic and anticonvulsant activity with reduced sedative/hypnotic/muscle relaxant/ataxic effects.... Agent: Wisys Technology Foundation, Inc. C/o Mirick, O'connell, Demallie & Lougee, LLP

20070299059 - Compostions and methods relating to novel compounds and targets thereof: The present invention relates to novel chemical compounds, methods for their discovery, and their therapeutic use. In particular, the present invention provides benzodiazepine derivatives and methods of using benzodiazepine derivatives as therapeutic agents to treat a number of conditions associated with the faulty regulation of the processes of programmed cell... Agent: Casimir Jones, S.c.

20070299060 - Cycloalkyl substituted pyrimidinediamine compounds and their uses: The present disclosure provides 2,4-pyrimidinediamine compounds having antiproliferative activity, compositions comprising the compounds and methods of using the compounds to inhibit cellular proliferation and to treat proliferate diseases such as tumorigenic cancers.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20070299061 - Fused [d]pyridazin-7-ones: The present invention is directed to fused [d]pyridazin-7-ones. The invention is also directed to methods for making and using the fused [d]pyridazin-7-ones. In particular, the compounds of the present invention may be effective in the treatment of diseases or disease states related to the activity of VEGFR2, MLK1 and CDK5... Agent: Cephalon, Inc.

20070299062 - Melanin concentrating hormone antagonists: The present invention relates to compounds capable of serving as moderators of human and mammalian appetite and as such provide a means for reducing body mass and controlling obesity.... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20070299063 - N3 alkylated benzimidazole derivatives as mek inhibitors: and pharmaceutically acceptable salts thereof, wherein W, R1, R2, R7, R8, R9 and R10 are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals. Also disclosed is a method of using such compounds in... Agent: Hogan & Hartson LLP

20070299064 - Pesticidal heterocyclic dihaloallyl compounds: Het, A1, A2, A3, A4, D, W, T, Q, Y, X1, X2, R1, R2, R3, R4, k and m are as defined hereinabove, and, where applicable, to possible E/Z isomers, mixtures of E/Z isomers and/or tautomers thereof, in each case in free form or in salt form, to a process... Agent: Syngenta Crop Protection , Inc. Patent And Trademark Department

20070299065 - Tetrahydropyran derivatives as antidiabetics: Novel compounds of the formula (I), in which T, E, R, R′, R″, R1, R2 and R2′ have the meanings indicated in patent Claim 1, are suitable as antidiabetics.... Agent: Millen, White, Zelano & Branigan, P.C.

20070299066 - Novel pyrimidothienoindazoles: v

20070299067 - Quinoline and isoquinoline derivatives as phosphodiesterase 10 inhibitors: The present invention is directed to certain quinoline and isoquinoline compounds that are PDE10 inhibitors, pharmaceutical compositions containing such compounds and processes for preparing such compounds. The invention is also directed to methods of treating diseases mediated by PDE10 enzyme, such as obesity, non-insulin dependent diabetes, schizophrenia, bipolar disorder, obsessive-compulsive... Agent: Jones Day

20070299070 - 2-arylcarboxamide-nitrogenous heterocycle compound: [wherein R1 and R2 are the same or different and each represents C1-6 alkyl, C3-8 cycloalkyl, et al; R3a, R3b, and R4 are the same or different and each represents hydrogen, C1-6 alkyl, et al; X represents —N—, —CH—, et al; Y, represents a single bond, C1-3 alkylene, et al;... Agent: Merck And Co., Inc

20070299068 - Methods for treating hepatitis c: The present invention provides compounds, pharmaceutical compositions, and methods of using such compounds or compositions for treating infection by a virus, or for affecting viral IRES activity.... Agent: Arnold & Porter LLP Attn:IPDocketing Dept.

20070299069 - Methods for treating hepatitis c: The present invention provides compounds, pharmaceutical compositions, and methods of using such compounds or compositions for treating infection by a virus, or for affecting viral IRES activity.... Agent: Arnold & Porter LLP Attn:IPDocketing Dept.

20070299071 - Substituted phenyl methanone derivatives: e

20070299073 - Imidazolyl derivatives: The present invention is directed to imidazolyl derivatives of formula (I) where the substituents are defined in the specification, which are useful as agonist or antagonists of somatostatin receptors.... Agent: Biomeasure, Incorporated

20070299072 - Kv1.5 potassium channel inhibitors: The present invention relates to 4-oxo-1,3,8-triaza-spiro[4.5]decanes which are useful as Kv1.5 potassium channel inhibitors providing atrial-selective antiarrhythmic activity. The present invention further relates to compositions and methods for treating atrial-selective antiarrhythmia.... Agent: Woodcock Washburn LLP/wyeth

20070299074 - Guanidine compounds, and use thereof as binding partners for 5-ht5 receptors: corresponding enantiomeric, diastereomeric and/or tautomeric forms thereof as well as pharmaceutically acceptable salts thereof. The present compound further relates to the use of guanidine compounds as binding partners for 5-HT5 receptors for the treatment of diseases which are modulated by a 5-HT5 receptor activity, in particular for the treatment of... Agent: Wood, Phillips, Katz, Clark & Mortimer

20070299075 - Novel inhibitors of kinases: and pharmaceutically acceptable salts thereof The formula I compounds inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2 and FGFR-1, thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through... Agent: Louis J. Wille Bristol-myers Squibb Company

20070299076 - Substituted 3-amino-pyrrolidino-4-lactams: d

20070299077 - Aryl-substituted polycyclic amines, method for the production thereof, and use thereof as a medicament:

20070299078 - Quinoxalinyl macrocyclic hepatitis c virus serine protease inhibitors: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned... Agent: Elmore Patent Law Group, PC

20070299079 - 4-amino-pyrido[3,2-e]pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them: The invention relates to 4-amino-pyrido[3,2-e]pyrazines, to processes for preparing them, to pharmaceutical preparations which comprise these compounds and to the pharmaceutical use of these compounds, which are inhibitors of phosphodiesterase 10, as active compounds for treating diseases of mammals including a human which can be influenced by using the compounds... Agent: Fulbright & Jaworski, LLP

20070299081 - Heterocyclic derivatives and their use as mediators of stearoyl-coa desaturase: Methods of treating an SCD-mediated disease or condition in a mammal, preferably a human, are disclosed, wherein the methods comprise administering to a mammal in need thereof a compound of formula (I): Formula (I) where x, y, G, J, L, M, V, W, R2, R3, R4, R5, R5a, R6, R6a,... Agent: Seed Intellectual Property Law Group PLLC

20070299082 - Novel azabicyclic aryl derivatives and their medical use: This invention relates to novel azabicyclic aryl derivatives, which are found to be cholinergic ligands at the nicotinic acetylcholine receptors and modulators of the monoamine receptors and transporters. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse... Agent: Birch Stewart Kolasch & Birch

20070299080 - Benzamide derivatives and uses related thereto: i

20070299083 - 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline hydrochloric acid salts: The present invention relates to hydrochloric acid salt and crystalline forms of the 5-HT1A binding agent 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline, as well as pharmaceutical compositions thereof, and methods of use thereof.... Agent: Fish & Richardson PC

20070299084 - Indole derivatives useful for treating resistance to antitumor agents: The use of a group of indole compounds of formula (I) is described for treating tumours which have developed resistance to antitumour drugs. The compounds of formula (I) can be used in monotherapy, to treat tumours affected by drug resistance, or in co-therapy, as synergistic enhancers of the action of... Agent: Jay S Cinamon Abelman Frayne And Schwab

20070299085 - N1-((pyrazol-1-ymethyl)-2-methylphenyl)-phatalamide derivatives and related compounds insecticides: Novel benzenedicarboxamides of the formula (I) wherein X represents hydrogen, halogen atom, nitro, C1-6alkylsulfonyloxy, C1-6alkylsulfinyl, C1-6alkylsulfenyl or C1-6alkylsulfonyl, R1 represents C1-6alkyl, C1-6alkylthio-C1-6alkyl, or C1-6alkyl, m represents 0 or 1, A represents O, S, SO, SO2, CH2 or CH(CH3), and Q represents a 5- or 6-membered heterocyclic group that contains at... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20070299086 - Prolyl hydroxylase inhibitors and methods of use: The present disclosure relates to HIF-1α prolyl hydroxylase inhibitors, compositions which comprise the HIF-1α prolyl hydroxylase inhibitors described herein and to methods for controlling, inter alia, Peripheral Vascular Disease (PVD), Coronary Artery Disease (CAD), heart failure, ischemia, and anemia.... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20070299087 - New compounds 319: e

20070299088 - Novel uses of 2-phenyl-substituted imidazotriazinone derivatives: The invention relates to the use of PDE 5 inhibitors, and especially of known 2-phenyl-substituted imidazotriazinone derivatives for producing medicaments for the treatment of symptoms that can be treated by increasing cGMP levels in certain tissues, such as acute myocardial infarction and damage caused by reperfusion, various symptoms in the... Agent: Jeffrey M. Greenman

20070299089 - Use of a2a adenosine receptor agonists in the treatment of ischemia: Methods for treating ischemia in mammals with one or more compounds that are agonists of mammalian adenosine A2A receptors.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20070299090 - Substituted 8-aminoalkoxy-xanthine compounds and compositions useful in the treatment of hyperlipidemia and diabetes: t

20070299091 - Azaindole carboxamides:

20070299092 - Quinone substituted quinazoline and quinoline kinase inhibitors: The present invention provides for compounds with the general formula: A compound of formula (1) having the structure (1) wherein Z is a radical selected from the group (a), (b), or (c) as well as methods and compositions containing these compounds useful for treatment of diseases that are characterized, at... Agent: Wyeth C/o Darby & Darby, P.C.

20070299094 - 4-(3-benzoylaminophenyl)-6,7-dimethoxy-2-methylaminoquinazoline derivatives: e

20070299093 - Organic compounds useful for the treatment of alzheimer's disease, their use and method of preparation: Compounds identified by the general formula (I) are used for the treatment of Alzheimer's disease.... Agent: Marshall, Gerstein & Borun LLP

20070299095 - Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds: The present invention provides methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds, as well as methods of treating, preventing or ameliorating symptoms associated with such diseases. Specific examples of autoimmune diseases that can be treated or prevented with the compounds include rheumatoid arthritis and/or its associated symptoms, systemic... Agent: Rigel Pharmaceuticals Inc.

20070299097 - Strategy for leukemia therapy: The chimeric Bcr-Abl oncoprotein is the molecular hallmark of chronic myelogenous leukemia (CML). In the cytoplasm, the protein transduces a growth signal that is responsible for overexpansion of cells. In the nucleus, the protein induces apoptosis. The invention is a method of treating cancer/killing Bcr-Abl expressing cells by inducing the... Agent: Biotactica, LLC

20070299096 - Treating learning deficits with inhibitors of hmg coa reductase: The disclosure provides methods of treating cognitive disorders by administering a HMG CoA reductase inhibitor. Cognitive deficits treatable with the inhibitor compound include those associated with Angelman Syndrome, Neurofibromatosis-1, certain forms of X-linked mental retardation, tuberous sclerosis, Down Syndrome, autism, and attention deficit/hyperactivity disorder.... Agent: Dorsey & Whitney LLP

20070299098 - Therapeutic agent for neuropathic pain: The present invention provides therapeutic agents for neuropathic pain, the agents having excellent therapeutic effects on neuropathic pain, which is an intractable disorder. More specifically, the invention provides therapeutic agents for neuropathic pain comprising, as the active ingredient, an opioid receptor antagonist (particularly naloxone, naltrexone, naloxonazine, naltrindole, etc.), pharmaceutical compositions... Agent: Foley And Lardner LLP Suite 500

20070299099 - Acid addition salt of irinotecan: The present invention is directed to an irinotecan acid addition salt which is formed through addition of an acid selected from the group consisting of sulfuric acid, nitric acid phosphoric acid, methanesulfonic acid, citric acid maleic acid and succinic acid to Irinotecan, to a method for producing the salt, and... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20070299100 - Analgesic: An analgesic which may be applied to wide variety of pain from various causes is disclosed. The analgesic comprises as an effective ingredient a specific morphinan derivative having a nitrogen containing heterocyclic group, such as compound 1:... Agent: Ip Group Of Dla Piper US LLP

20070299101 - Niacin receptor agonists, compositions containing such compounds and methods of treatment: The present invention relates to niacin receptor agonists of formula: (I); as well as pharmaceutically acceptable salts and solvates. The compounds are useful for treating dyslipidemias, and in particular, reducing serum LDL, VLDL and triglycerides, and raising HDL levels. Pharmaceutical compositions and methods of treatment are also included.... Agent: Merck And Co., Inc

20070299102 - Diphenyl ox-indol-2-one compounds and their use in the treatment of cancer: e

20070299103 - [1,2,4]triazolo[4,3-a]pyridine derivatives for the treatment of hyperproliferative diseases: The invention provides novel, substituted 7-arylamino[1,2,4]triazolo[4,3-a]pyridine compounds Formula (I): pharmaceutically acceptable salts, solvates and prodrug compounds thereof, wherein W, R1, R2, R9, R10 R11, R12, R13, R14 and L are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20070299104 - Tetrahydropyranyl cyclopentyl 1-substituted and 1,1-disubstituted tetrahydroisoquinoline modulators of chemokine receptor activity: Compounds of Formula I: I (wherein n, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R15, R16, Y and Z are as defined herein) which are modulators of chemokine receptor activity and are useful in the prevention or treatment of certain inflammatory and immunoregulatory disorders and diseases, allergic... Agent: Merck And Co., Inc

20070299105 - 2-cyanopropanoic acid amide and ester derivatives and methods of their use: m

20070299107 - N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors: The invention relates to N-hydroxysulfonamide derivatives that donate nitroxyl (HNO) under physiological conditions and are useful in treating and/or preventing the onset and/or development of diseases or conditions that are responsive to nitroxyl therapy, including heart failure and ischemia/reperfusion injury. Novel N-hydroxysulfonamide derivatives release NHO at a controlled rate under... Agent: Morrison & Foerster LLP

20070299108 - New heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-bacterial agents: e

20070299106 - Novel mycobacterial inhibitors:

20070299109 - Dimeric compounds of piperidine, piperazine or morpholine or their 7-membered analogs suitable for the treatment of neurodegenerative disorders: Formula (I″), the N-oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof.... Agent: Philip S. Johnson Johnson & Johnson

20070299110 - Novel tetrazole derivatives as positive allosteric modulators of metabotropic glutamate: The present invention relates to new tetrazole compounds of formula I wherein B, P, Q, W, R1 and R2 are defined in the description: invention compounds are useful for the treatment or prevention of central nervous system disorders as well as other disorders modulated by mGluR5 receptors.... Agent: Edwards Angell Palmer & Dodge LLP

20070299111 - Benzamide derivatives and uses related thereto: Benzamide derivatives of formula I are described and have therapeutic utility, particularly in the treatment of diabetes, obesity and related conditions and disorders:... Agent: Foley And Lardner LLP Suite 500

20070299113 - Metabotropic glutamate receptor modulators: The invention relates to imidazothiazole derivatives as well as their pharmaceutically acceptable salts. The invention further relates to a process for the preparation of such compounds. The compounds of the invention are group I mGluR modulators and are therefore useful for the control and prevention of various disorders, including acute... Agent: The Firm Of Hueschen And Sage

20070299112 - Substituted thienopyrrole carboxylic acid amides, pyrrolothiazole carboxylic acid amides, and related analogs as inhibitors of casein kinase i: as inhibitors of human casein kinase Iε and methods for using said compounds for treating central nervous system diseases and disorders including mood disorders and sleep disorders. Pharmaceutical compositions comprising compounds of formula (I) or formula (II) and a method for the preparation of compounds of formula (I) or formula... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20070299114 - Biaryl derivatives:

20070299115 - (hetero)cyclyl(thio) carboxylic acid anilides for controlling pathogenic fungi: The invention relates to (hetero)cyclyl(thio)carboxylic acid anilides of general formula (I) and to salts of said anilides that can be used for agricultural purposes for controlling pathogenic fungi. In said formula, the variables are defined as follows: A represents a phenyl or at least a monounsaturated 5- or 6-membered heterocycle... Agent: Birch Stewart Kolasch & Birch

20070299116 - Human protein tyrosine phosphatase inhibitors and methods of use: The present disclosure relates to compounds effective as human protein tyrosine phosphatase beta (HPTP-β) inhibitors thereby regulating angiogenesis. The present disclosure further relates to compositions comprising one or more human protein tyrosine phosphatase beta (HPTP-β) inhibitors, and to methods for regulating angiogenesis.... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20070299117 - Hydroxypropylaimines: and the pharmaceutically acceptable salts thereof wherein the variables RN, R1, R2, R3, Rp and RC are defined herein. These compounds are useful in treating Alzheimer's disease and other similar diseases. These compounds include inhibitors of the beta-secretase enzyme that are useful in the treatment of Alzheimer's disease and other... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20070299118 - Benzoxazolone derivatives, processes for preparing them and their uses: The present invention relates to benzoxazolone derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals, in the treatment of movement disorders, in particular in Parkinson's disease.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20070299119 - Prophylactic or therapeutic agent for severe diabetic retinopathy: wherein X represents a halogen or a hydrogen atom, R1 and R2 concurrently or differently represent a hydrogen atom or an optionally substituted C1 to C6 alkyl group, or R1 and R2, together with a nitrogen atom bound thereto and optionally another nitrogen atom or an oxygen atom, are combined... Agent: Burr & Brown

20070299120 - Kv1.5 potassium channel inhibitors: The present invention relates to 1-N-amino-2-imidazolidinones and derivatives thereof which are effective as Kv1.5 potassium channel inhibitors providing atrial-selective antiarrhythmic agents. The present invention further relates to compositions comprising said Kv1.5 potassium channel inhibitors, and to methods for treating cardiac arrhythmia.... Agent: Woodcock Washburn LLP/wyeth

20070299121 - Transmucosal veterinary composition comprising detomidine: The present invention relates to a veterinary composition in a semisolid form adapted for transmucosal administration for providing sedation and analgesia in large animals such as horses and cattle. The semisolid transmucosal composition of the invention comprises detomidine or a pharmaceutically acceptable salt thereof as an active ingredient. The composition... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070299123 - Amorphous frovatriptan succinate and process for the preparation thereof: Frovatriptan succinate substantially in an amorphous form is disclosed. Also disclosed is a composition comprising frovatriptan succinate in a solid form, wherein at least about 80% by weight of the solid is frovatriptan succinate in an amorphous form. The present invention also provides a process for preparing frovatriptan succinate substantially... Agent: M. Carmen & Associates, PLLC

20070299122 - Method of treating pathological blushing: A method of treating pathological blushing is disclosed wherein the patient is administered a DP receptor antagonist. Compositions containing DP antagonists are also included.... Agent: Merck And Co., Inc

20070299124 - Formulations and methods for treating dry eye: The present invention provides compositions for treating and/or preventing signs and symptoms associated with dry eye and/or ocular irritation, and methods of use thereof. Such compositions are provided in novel ophthalmic formulations that are comfortable upon instillation in the eye.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.C.

20070299125 - Substituted indoles: The present invention relates generally to substituted indoles and methods of using them.... Agent: Woodcock Washburn LLP/wyeth

20070299126 - Substituted pyrrole-indoles: The present invention relates generally to substituted pyrrole-indoles such as substituted pyrrole-indoles, and methods of using them.... Agent: Woodcock Washburn LLP/wyeth

20070299127 - Compositions and kits comprising a melatonin component and an omega-3-fatty acid component: Disclosed herein are compositions and kits, wherein each composition comprises a melatonin component, an omega-3-fatty acid component, or both, and wherein each kit comprises a melatonin component and an omega-3-fatty acid component. The compositions and kits are useful for restorative sleep function and skin benefits. Further disclosed herein are methods... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20070299128 - Use of tryptophan derivatives for the specific cytostatic treatment of serotonin-producing tumors: The invention relates to the use of tryptophane-derivatives for the specific cytostatic treatment of serotonin-producing tumors, such as, for example carcinoids and the like. Areas of application of the invention are in the field of medicine and pharmaceutical industry.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20070299129 - Compounds and derivatives for the treatment of medical conditions by modulating hormone-sensitive lipase activity: The present invention discloses compounds that are inhibitors of hormone-sensitive lipase. The present invention also discloses the use of the compounds and derivatives to inhibit hormone-sensitive lipase, various pharmaceutical compositions including the compounds, and methods of treatment using these compounds and compositions.... Agent: Marshall, Gerstein & Borun LLP

20070299130 - Benzopyran compound: wherein X is NR6, Y is a bond, SO or SO2, Z is C1-4alkyl group or phenyl group, W is hydrogen atom, hydroxy group, C1-6 alkoxy group, a halogen atom, C1-4alkyl group or C1-6alkylsulfonylamino group, R1 and R2 are independently of each other C1-3alkyl group, R3 is hydrogen atom, hydroxy... Agent: Oliff & Berridge, PLC

20070299131 - Furancarbonylguanidine derivatives, their preparation and pharmaceutical compositions containing them: The present invention relates to furancarbonylguanidine derivatives, a preparation method thereof and a pharmaceutical composition comprising the same. Furancarbonylguanidine derivatives of the present invention inhibit NHE-1 (sodium-hydrogen exchanger isoform 1), which helps recovery of heart function damaged from ischemia/reperfusion and decreases myocardial infarction rate, indicating that they have protective effect... Agent: Lucas & Mercanti, LLP

20070299132 - Stable aqueous formulation of a platin derivative: Disclosed is a stable aqueous formulation of a platin derivative, particularly oxaliplatin. The selected stabilizing additive is effective even in very small concentrations.... Agent: Wenderoth, Lind & Ponack, L.L.P.

20070299134 - Concentrated and odorless omega 3 fatty acids: A blend of triglycerides having the general formula CH2(OOC-R1)—CH(OOC—R2)—CH2(OOC—R3), wherein at least about 50% of the R1, R2 and R3 groups have a chain length of C19 or more. The blend of triglycerides has less than about 50 parts per billion (ppb) of trimethyl amine, that is, they are substantially... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20070299133 - Concentrated omega-3 fatty acids and mixtures containing them: A stable aqueous emulsion comprising water, a blend of esters including esters of polyunsaturated fatty acids, such as omega-3 fatty acids, emulsifiers and stabilizers is disclosed. The emulsion may be used as a beverage or as an additive that may be added to a beverage or a food product. The... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20070299135 - Compositions for use in surgery: A method is provided for treating a subject in need of medication as an adjunct to elective surgery, comprising administration of a ketogenic material sufficient to produce a physiologically acceptable ketosis in the patient. Preferably the surgery is selected from the groups consisting of removal or section of tumours, removal... Agent: Nixon & Vanderhye, PC

20070299136 - Crystalline and amorphous forms of efaproxiral sodium: There are provided in accordance with the present invention crystalline forms A, B, C, F, G, I, J, P, and Q of efaproxiral sodium. Also provided is the amorphous form of efaproxiral sodium. Also provided are methods of forming the novel polymorphs and the amorphous form of efaproxiral sodium, therapeutic... Agent: Swanson & Bratschun, L.L.C.

20070299137 - N-acylated derivatives of dicarboxylic acids with amino acids and vegetable protein hydrolsates and their use in cosmetics and pharmaceuticals: X and Y, which can be the same or different, are OM or a residue of formula MOOCHRNH— wherein R is the residue of a natural alpha-amino acid and M is hydrogen or a non toxic cation, or X and/or Y are a —NH—P residue, wherein P is a polypeptide... Agent: Young & Thompson

20070299138 - St104p, an anti-angiogenic agent: The present invention relates to a method of treating a subject suffering non-tumor condition or disease associated with angiogenesis which comprises administering the subject in need of the treatment with an effective angiogenesis inhibiting dose of a tetrameric cyclic compound of 4,5-dihydroxynaphthalene-2,7, disulfonic acid linked by methylene bridges in a... Agent: Wpat, PC Intellectual Property Attorneys

20070299139 - Lyophilisate comprising n-diaminomethylene-2-methyl-4,5-di(methylsulfonyl)benzamide: The invention relates to a lyophilisate comprising N-diaminomethylene-2-methyl-4,5di(methylsulfonyl)benzamide as active compound. The composition has increased storage stability, even at elevated temperatures, and can be administered parenterally as medicament after reconstitution.... Agent: Millen, White, Zelano & Branigan, P.C.

20070293427 - Hydrolysate of avian cartilage, process of preparation and uses thereof: This invention relates to a hydrolysate of avian cartilage comprising 45% to 70% by weight of hydrolysed type II collagen, 9% to 15% by weight of chondroitin sulphate, 0.5% to 2% in weight of hyaluronic acid; with a composition of amino acids in which valine represents 2.7% to 3.3%, isoleucine... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070293428 - Methods of treating joint pain in a subject by using an anti-angiogenic agent: A method for treating a joint pain in a subject comprising providing an effective amount of an anti-angiogenic agent to a synovial capsule adjacent to the joint.... Agent: Fox Rothschild, LLP

20070293435 - Identification and use of non-peptide analogs of rnaiii-inhibiting peptide for the treatment of staphylococcal infections: RNAIII inhibiting peptide (RIP) has been established as an effective inhibitor of staphylococcal infections. Non-peptide small molecule analogs based on a pharmacophore conforming to the putative atomic structure of RIP, can be identified by computer screening of that pharmacophore against established libraries of known small molecules other than peptides. One... Agent: Jagtiani + Guttag

20070293445 - Stable elsamitrucin salts suitable for pharmaceutical formulations: Stable solid, crystalline forms of elsamitrucin salts are provided that are useful in preparing anti-neoplastic parenteral formulations. Also provided are methods for treating neoplastic diseases in humans using parenteral formulations that include at least one stable elsamitrucin salt.... Agent: Kirkpatrick & Lockhart Preston Gates Ellis LLP

20070293416 - Ceacam based antibacterial agents: Prophylactic and/or therapeutic antipathogen agents are provided that disrupt or prevent the formation of at least one homotypic and/or heterotypic protein-protein interaction that has at least one CEA-family protein and that is involved in the establishment and colonization of a pathogen in a suitable host.... Agent: Mcandrews Held & Malloy, Ltd

20070293415 - Composition containning flavan compound: A composition comprising: a flavan compound that is at least one of a proanthocyanidin and catechins; a protein degradation peptide having an average molecular weight of less than 7,000; and a peptide or protein having an average molecular weight of not less than 7,000. The composition does not impair effects... Agent: The Webb Law Firm, P.C.

20070293418 - Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis: The invention is directed to a pharmacologically active peptide conjugate having a reduced tendency towards enzymatic cleavage comprising a pharmacologically active peptide sequence (X) and a stabilising peptide sequence (Z) of 4-20 amino acid residues covalently bound to X.... Agent: Clark & Elbing LLP

20070293417 - Polyamides for treating human papilloma virus: The present invention relates to polyamide compositions and therapies for treating cells infected with human papilloma virus (HPV).... Agent: Jonathan P. O'brien Miller, Canfield, Paddock And Stone

20070293421 - Erythropoietin for treatment of multi-organ failure: The compositions and methods disclosed herein are for prevention or treatment of multi-organ failure with erythropoietin. The usefulness of the present invention is that erythropoietin may act to prevent the onset of MOF in a patient at risk of developing it. The present invention may further lessen the effect in... Agent: The Mccallum Law Firm, P. C.

20070293420 - Method for purifying erythropoietin: The invention relates to a method for producing recombined erythropoietin having a particularly high degree of purity (≧98%). The method consists of at least 5 chromatographic purification steps, i.e. at least two anion exchange chromatographs, at least one hydrophobic interaction chromatography, at least one affinity chromatography and at least one... Agent: Knobbe Martens Olson & Bear LLP

20070293419 - Stable, aqueous solution of human erythropoietin, not containing serum albumin: The present invention provides an aqueous formulation of human erythropoietin having the storage stability over a long period without serum albumin, in which the formulation comprises a pharmaceutically effective amount of human erythropoietin; non-ionic surfactant, polyhydric alcohol, neutral amino acid and sugar alcohol as stabilizers; isotonic reagent; and buffering reagent.... Agent: Cantor Colburn, LLP

20070293424 - Antitumoral and antiviral peptides: The invention relates to novel compositions of general formula (1) consisting of X1 Trp Gly Gln X2 or the pharmaceutically acceptable salts or esters or amides thereof, wherein X1 is absent or contains at least one type of aminoacid, X2 is absent or contains at least one type of aminoacid.... Agent: Renner Otto Boisselle & Sklar, LLP

20070293422 - Beta-amyloid inhibitors and use thereof: Peptides and derivatives or analogs thereof are provided for having β-amyloid aggregation inhibitory activity, useful in the treatment and prevention of diseases such as Alzheimer's disease, Dementia pugilistica (including head trauma), Hereditary Cerebral Haemorrhage with amyloidosis of the Dutch type (HCHWA-D) and vascular dementia with amyloid angiopathy.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20070293423 - Compounds, methods and formulations for the oral delivery of a glucagon-like peptide (glp)-1 compound or a melanocortin-4 receptor (mc4) agonist peptide: The present invention relates to novel compounds, methods, and formulations useful for the oral delivery of a GLP-1 compound or an MC4 agonist peptide.... Agent: Eli Lilly & Company

20070293431 - Method for improving neurotransmission failure using a novel agent: A novel medicament for ameliorating neurotransmission dysfunction diseases is provided. A medicament for ameliorating neurotransmission dysfunction diseases comprising as a main active ingredient preferably a selenocysteine-containing protein such as Selenoprotein P or a selenocysteine-containing peptide that consists of said protein or a series of said peptides. A medicament suited for... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20070293426 - Methods for improving islet signaling in diabetes mellitus and for its prevention: The present invention discloses methods for therapeutically treating mammals, including but not limited to humans, to increase the relative insulin producing performance of endogenous pancreatic β-cells, to cause differentiation of pancreatic epithelial cells into insulin producing β-cells, to improve muscle sensitivity to insulin and other weight control efforts by the... Agent: Osi Pharmaceuticals, Inc.

20070293433 - Methods of treating aging of skin with oligosaccharides in cosmetic or dermatological compositions that stimulate adhesion of keratinocytes to major proteins of the dermoepidermal junction and restore epidermal cohesion: A method of treating aging of skin including applying a therapeutically effective amount of an anti-aging dermatological care composition including at least one cosmetic formulation agent and oligogalacturonides having a degree of polymerization between 1 and 5 that stimulates adherence of basal keratinocytes to laminin V and/or collagen IV and... Agent: Ip Group Of Dla Piper US LLP

20070293425 - Mutein of a bone morphogenetic protein and use thereof: The present invention is related to a mutein of a bone morphogenetic protein, whereby the mutein comprises an amino acid substitution compared to the wildtype of the bone morphogenetic protein at the amino acid position corresponding to amino acid position 51 of human BMP-2.... Agent: Fish & NeaveIPGroup Ropes & Gray

20070293430 - Muteins of fibroblast growth factor 21: The present invention relates to novel muteins of human fibroblast growth factor 21 with reduced deamidation compared to wild-type human FGF-21. Both protein and the respective encoding nucleic acid species are disclosed. The invention also embodies vectors and host cells for the propagation of said nucleic acid sequences and the... Agent: Eli Lilly & Company

20070293429 - Vasoactive intestinal polypeptide compositions: Pharmaceutical compositions relating to vasoactive intestinal polypeptides and methods for the treatment of metabolic disorders, including diabetes, insulin resistance, metabolic acidosis and obesity are presented. Methods of using the vasoactive intestinal polypeptide compositions are also disclosed.... Agent: Forbes Medi-tech Inc. Attention: Ms. Susan M. Ben-oliel

20070293432 - Vegf antagonist formulations suitable for intravitreal administration: Ophthalmic formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided suitable for intravitreal administration to the eye. The ophthalmic formulations include a stable liquid formulation and a lyophilizable formulation. Preferably, the protein antagonist has the amino acid sequence shown in SEQ ID NO:4.... Agent: Regeneron Pharmaceuticals, Inc

20070293434 - Binding polypeptides and methods based thereon: Binding polypeptides that specifically bind BLyS protein or BLyS-like polypeptides can be used in methods of the invention for detecting, diagnosing, or prognosing a disease or disorder associated with aberrant BLyS or BLyS receptor expression or inappropriate function of BLyS or BLyS receptor, comprising BLyS binding polypeptides or fragments or... Agent: Leydig, Voit & Mayer Ltd.

20070293436 - Cytoprotective thereapeutic agents for the prevention of reperfusion injury following ischemic stroke: The present invention relates generally to the use of γ-glutamyl antioxidants, particularly γ-glutamyl-cysteine, as cytoprotective agents to prevent reperfusion injury (i.e., hemorrhagic transformation) of the blood-brain barrier during reperfusion following an ischemic stroke. The γ-glutamyl antioxidants can be used alone or used in combination with an agent which inhibits the... Agent: Joseph A. Fuchs Rockey, Depke & Lyons, LLC

20070293438 - Antibody specifically binding to sulfonylated protein protein and method for producing the same: Provided is a method for producing an antibody binding to a sulfonylated isoform of a protein; not to a non-sulfonylated isoform of the protein and other proteins, including: providing a peptide comprised of 6 to 15 amino acids derived from the protein and having a sulfonylated cysteine residue; inducing an... Agent: Lowe Hauptman Ham & Berner, LLP

20070293437 - Expression profiling platform technology: The present invention relates to an efficient mAb panel-based expression profiling technology platform suitable for global and accurate measurement of proteins, peptides and metabolites in complex mixtures. The platform is comprised of new and well established technologies that are coupled in a unique fashion to provide a novel platform technology... Agent: Nixon & Vanderhye, PC

20070293440 - Co-therapy for the treatment of epilepsy and related disorders: The present invention is directed to co-therapy for the treatment of epilepsy and related disorders comprising administering to a subject in need thereof, co-therapy with a therapeutically effective amount of a benzo-fused heterocycle sulfamide derivative and a therapeutically effective amount of one or more anticonvulsant and/or anti-epileptic agents.... Agent: Philip S. Johnson Johnson & Johnson

20070293441 - High-pressure sterilization to terminally sterilize pharmaceutical preparations and medical products: The present disclosure provides a sterilized medical system that includes an ultra high pressure sterilized glucose solution in a container. The sterile glucose solution may contain less than about 40 ppm total glucose degradation product. The glucose solution may be a ready-to-use infusion solution disposed in a single chamber container.... Agent: Baxter Healthcare Corporation

20070293439 - Methods and compositions for treating hyperglycemic, hyperlipidemic, or hyperinsulinemic disorders: Methods of treating hyperglycemic, hyperlipidemic, and hyperinsulinemic disorders are provided. Compositions for treating such disorders are also provided. The compositions can include hexose and pentose variants having acid moieties and a substituent Y linked to the six position of a hexose or the five position of the pentose.... Agent: Calfee Halter & Griswold, LLP

20070293442 - Antithrombotic compound: t

20070293443 - Composition for accelerating calcium absorption: The present invention relates to a composition for accelerating calcium absorption containing a poorly absorbable L-form aldonic acid, a salt thereof, or a poorly absorbable L-form aldonolactone. The invention also relates to a food or beverage containing L-arabonic acid, a salt thereof, or L-arabonolactone. The invention also relates to a... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20070293446 - Compositions comprising c-13 alkoxyether macrolide compounds and phenylpyrazole compounds: e

20070293444 - Novel nucleoside transport inhibitors: Compounds or compositions that are inhibitors and/or ligands of nucleoside transporters; and methods of treating cancer, heart disease and stroke, as well as AIDS and other infectious diseases... Agent: John K. Buolamwini

20070293452 - Agents, compositions and methods for treating pathologies in which regulating an ache-associated biological pathway is beneficial: The present invention provides agents which are capable of regulating the function of a micro-RNA component which can be used to regulate an ACHE-associated biological pathway. In addition, the present invention provides methods and pharmaceutical compositions for the treatment of various pathologies related to AChE-associated biological pathways such as apoptosis,... Agent: Martin D. Moynihan Prtsi, Inc.

20070293453 - Combinatorial methods for inducing cancer cell death: The present invention relates to methods and compositions for inhibiting proliferation and inducing cell death in a population of cancer cells by (i) increasing the amount of the differentiation associated protein MDA-7, and (ii) decreasing RAS activity within the population. It is based, at least in part, on the discovery... Agent: Baker Botts L.L.P.

20070293449 - Compositions and methods for delivery of double-stranded rna: Pharmaceutical compositions and methods of use of a composition containing a double-stranded RNA (dsRNA), cationic lipids, non-cationic lipids, and lipophilic delivery-enhancing compounds.... Agent: Nastech Pharmaceutical Company Inc

20070293447 - Gene therapy for skin disorders using needleless syringes: The present invention provides highly useful clinical methods for treating skin disorders, particularly intractable skin disorders. Specifically, the methods comprise injecting/subcutaneously introducing a 10 μg to 10 mg dose of a polynucleotide, such as a DNA, oligonucleotide, RNA, siRNA, and antisense, around a lesion associated with a skin disorder, such... Agent: Townsend And Townsend And Crew, LLP

20070293450 - Identification of ses-3 and the uses of same: The invention relates to isolated nucleic acid molecules coding for SES-3 proteins or muted SES-3 proteins, and vectors and transgenic organisms containing such nucleic acid molecules. The invention also relates to uses of such nucleic acid molecules or others which are functionally similar, for producing pharmaceuticals and for producing model... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20070293451 - Regulation ao apob by hsp110 proteins and related compositions and methods: Hsp110 proteins are shown herein to stabilize nascent ApoB protein. Methods of down-regulating expression of ApoB, and thus down-regulating serum cholesterol levels, are therefore, provided, including, without limitation, inhibition of Hsp110 expression by any method, for example and without limitation, by RNA interference (RNAi). It also has been found that... Agent: Jesse A. Hirshman, Esq.

20070293448 - Synthetic gagpol genes and their uses: The present invention relates to synthetic gag and gagpol genes optimized for high level expression via codon optimization and the uses thereof for the efficient generation of vector particles. The invention further relates to the generation of packaging cells and vaccines based on the synthetic gag and gagpol genes.... Agent: Fulbright & Jaworski L.L.P.

20070293454 - Complex containing mequitazine, a cyclodextrin and an interaction agent: The present invention relates to a complex that includes mequitazine, a cyclodextrin, and an interaction agent wherein the rate of solubilization in water of complexed mequitazine, measured for a 2 g/l mixture of mequitazine in water at 35° C. after 15 minutes of stirring, is greater than 50% at pH... Agent: Birch Stewart Kolasch & Birch

20070293456 - Method for the synthesis of 3-substituted indolizine and benzoindolizine compounds: e

20070293455 - Silylated carboxamides:

20070293457 - Boron-containing small molecules as anti-inflammatory agents: Methods of treating anti-inflammatory conditions through the use of boron-containing small molecules are disclosed.... Agent: Morgan, Lewis & Bockius LLP (sf)

20070293458 - Prevention of nuclear, solar, and other radiation-induced tissue damage: Inositol hexaphosphate (IP-6) is a polyphosphorylated carbohydrate with potent antioxidant activity to prevent active oxygen species-mediated mutagenesis, cell injury and carcinogenesis. IP-6 also activates DNA repair mechanisms. Sublethal radiation causes DNA damage through the formation of free radicals, reactive oxygen species, and pyrimidine crosslinks leading to cellular proliferation, cell cycle... Agent: Bingham Mccutchen LLP

20070293459 - Method for inhibiting cellular na+-k+ atpase activity: The present invention discloses an inhibitive effect of Na+—K+-ATPase caused by a compound selected from the group consisting of magnesium lithospermate B (MLB), isomer, prodrug, derivative, pharmaceutically acceptable salt, and a composition thereof. In this invention, the variations of Na+—K+-ATPase activity were monitored with increasing MLB concentrations, and the result... Agent: Pai Patent & Trademark Law Firm

20070293461 - Biphenyl compounds useful as muscarinic receptor antagonists: wherein a, b, c, d, m, n, p, r, R1, R2, R3, R4, R5, R6, R7, and W are as defined in the specification. The compounds of formula I are muscarinic receptor antagonists. The invention also provides pharmaceutical compositions containing such compounds, processes and intermediates for preparing such compounds and... Agent: Theravance, Inc.

20070293460 - Delivery of a combination therapy for asthma and chronic obstructive pulmonary disease: A method of delivery of a combination therapy to the pulmonary system that includes providing a nebulizer and an aqueous solution comprising a long-acting corticosteroid, a long-acting beta-agonist, and a long-acting anticholinergic, and administering the solution to the patient using the nebulizer. The corticosteroid is budesonide, the beta-agonist is formoterol... Agent: Akerman Senterfitt

20070293462 - Method for inhibiting cellular na+-k+ atpase activity: The present invention discloses an inhibitive effect of Na+-K+-ATPase caused by a compound selected from the group consisting of magnesium lithospermate B (MLB), isomer, prodrug, derivative, pharmaceutically acceptable salt, and a composition thereof. In this invention, the variations of Na+-K+-ATPase activity were monitored with increasing MLB concentrations, and the result... Agent: Pai Patent & Trademark Law Firm

20070293463 - Method for shortening hospital stay in patients with congestive heart failure and acute fluid overload: Methods of treating patients with acute fluid overload comprising administering diuretic therapy and an amount of KW-3902, a pharmaceutically acceptable salt, ester, amide, metabolite, or prodrug thereof, effective to accelerate removal of excess fluid from the patient in comparison to diuretic therapy alone. Methods of improving the treatment time to... Agent: Knobbe Martens Olson & Bear LLP

20070293464 - Substituted pyrimidine compositions and methods of use: Novel compositions and methods of using substituted pyrimidines which have the general formula: (I)... Agent: Mcdonnell Boehnen Hulbert @ Berghoff LLP

20070293465 - Compounds for enzyme inhibition: One aspect of the invention relates to inhibitors that preferentially inhibit immunoproteasome activity over constitutive proteasome activity. In certain embodiments, the invention relates to the treatment of immune related diseases, comprising administering a compound of the invention. In certain embodiments, the invention relates to the treatment of cancer, comprising administering... Agent: Ropes & Gray LLP Patent Docketing 39/41

20070293466 - Antimicrobial chelates: Methods useful for inhibiting growth of a variety of microbes including bacteria and fungi are disclosed. The methods involve contacting a microbe with an inhibitory amount of a zinc chelate. Methods useful for preserving a consumable product are also disclosed.... Agent: Brinks Hofer Gilson & Lione / Albion Utah Office

20070293467 - Demethyl-cantharidin platinum complex isomers and their use: The present invention provides a stereo-isomer of the demethylcantharidin platinum complex of formula I and use thereof. The stereo-isomer inhibits the growth of cisplatin, carboplatin or oxaliplatin-sensitive and -resistant tumorous cells. The invention also describes a pharmaceutical composition comprising the stereo-isomer of the demethylcantharidin platinum complex and use thereof.... Agent: Knobbe Martens Olson & Bear LLP

20070293468 - Anticancer compositions, and methods of making and using the same: e

20070293469 - Compositions and methods for the treatment and prevention of disease: The present invention relates to various novel substituted dipeptide derived nitrogen-containing heterocyclic compounds, their pharmaceutically acceptable salt derivatives, and their methods of use. In one aspect the present invention relates to compositions and methods for the treatment and prevention of disease in a mammal comprising administering the compounds of the... Agent: Mccarter & English LLP Cityplace I

20070293470 - Carboxamide spirolactam cgrp receptor antagonists: The present invention is directed to compounds of Formula I: I (where variables A1, A2, B, J, K, m, n, R4, R5a, R5b and R5c are as defined herein) useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved,... Agent: Merck And Co., Inc

20070293471 - Industrial preparation of 11-[4-{2-(2-hydroxyethoxy) ethyl}-1-piperazinyl] dibenzo [b,f]-[1,4]thiazepine: Disclosed herein is an industrial preparation of Quetiapine by the reaction of 11-piperazinyldibenzo[b,f][1,4]-thiazepine or its salt with 2-(2-chloroethoxy)ethanol in presence of an organic or inorganic base under neat or aqueous condition to form 11-[4-{2-(2-hydroxyethoxy)ethyl}-1-piperazinyl]dibenzo[b,f]-[1,4]thiazepine. The quetiapine free base obtained is further converted to its hemi-fumarate salt.... Agent: Blank Rome LLP

20070293472 - Novel 14 and 15 membered ring compounds: s

20070293473 - Use of acylaminoalkenylene-amide derivatives in functional motility disorders of the viscera:

20070293474 - Combination of a dpp iv inhibitor and a cardiovascular compound: The present invention relates to a combination, such as a combined preparation or pharmaceutical composition, respectively, comprising of a DPP IV inhibitor or a pharmaceutically acceptable salt thereof and a cardiovascular compound (being different from statin) or a pharmaceutically acceptable salt thereof. The present invention furthermore relates to the use... Agent: Novartis Corporate Intellectual Property

20070293475 - Aryl and heteroaryl tetrahydrobenzazepine derivatives and their use for treating glaucoma: Aryl tetrahydrobenzazepine derivatives with minimal 5-HT2B activity relative to 5-HT2A and 5-HT2C activity that are useful for treating glaucoma are disclosed.... Agent: Alcon

20070293476 - Co-therapy for the treatment of epilepsy and related disorders: The present invention is directed to a method for the treatment of epilepsy and related disorders comprising administering to a subject in need thereof, co-therapy with a therapeutically effective amount of a benzo-heteroaryl sulfamide derivative as described herein and a therapeutically effective amount of one or more anticonvulsant and/or anti-epileptic... Agent: Philip S. Johnson Johnson & Johnson

20070293477 - Novel compounds: e

20070293478 - Substituted quinolones: The invention relates to substituted quinolones and to processes for their preparation as well as to their use for the production of medicaments for the treatment and/or prophylaxis of diseases, especially for use as antiviral agents, particularly against cytomegaloviruses.... Agent: Morrison & Foerster LLP

20070293479 - Olanzapine pharmaceutical composition: An olanzapine pharmaceutical composition is formed using anhydrous calcium hydrogen phosphate. The composition can be tabletted by dry processes and typically has good stability.... Agent: SynthonIPInc

20070293481 - Treating obesity with muscarinic receptor m1 antagonists: Provided are methods of treating obesity and effecting desired weight loss or preventing undesired weight gain by administration of a preferential muscarinic acetylcholine receptor M1 antagonist, optionally with at least one antidepressant other than a selective muscarinic acetylcholine receptor M1 antagonist. The preferential muscarinic acetylcholine receptor M1 antagonist, optionally can... Agent: Townsend And Townsend And Crew, LLP

20070293480 - Treating psychological conditions using muscarinic receptor m1 antagonists: Provided are methods of treating psychological diseases and conditions by administration of a preferential muscarinic acetylcholine receptor M1 antagonist, optionally with at least one antidepressant other than a selective muscarinic acetylcholine receptor M1 antagonist. The invention also provides for pharmaceutical compositions and kits for administration of at least one selective... Agent: Townsend And Townsend And Crew, LLP

20070293482 - Process for preparing benzodiazepines: o

20070293483 - Acetyl 2-hydroxy-1, 3-diaminoalkanes:

20070293484 - Thiophene heteroaryl amines: The present invention relates to thiophene heteroaryl amines and their pharmaceutically acceptable salts that modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer.... Agent: Pfizer Inc

20070293485 - Drug administration methods: Provided herein are methods for administering an efficacious amount of a compound of Formula I that reduce the severity of a potential adverse effect or obviate a potential adverse effect.... Agent: Morrison & Foerster LLP

20070293486 - Alpha-keto carbonyl calpain inhibitors: The present invention relates to novel α-keto carbonyl calpain inhibitors for the treatment of neurodegenerative diseases and neuromuscular diseases including Duchenne Muscular Dystrophy, Becker Muscular Dystrophy and other muscular dystrophies. Disuse atrophy and general muscle wasting can also be treated. Diseases of the eye, in particular cataract, can be treated... Agent: Kilyk & Bowersox, P.l.l.c.

20070293487 - Benzothiazole- and benzooxazole-4,7-dione, derivatives and their use as cdc25 phosphate inhibitors: The invention concerns the use as cdc25 phosphatase inhibitors, in particular cdc25-C phosphatase, and CD45 phosphatase, of compounds of general formula (I), wherein: W represents O or S. In accordance with the invention, the compounds of general formula (I) can in particular be used for preparing a medicine for cancer... Agent: Hunton & Williams LLP Intellectual Property Department

20070293488 - N,n'-diphenylurea derivatives suitable as kinase inhibitors: Compounds of the formula (I), in which R1, R3 and X have the meanings indicated in claim 1, are inhibitors of tyrosine kinases, in particular TIE-2, and Raf kinases and can be employed, inter alia, for the treatment of tumours.... Agent: Baker & Daniels LLP

20070293489 - Substituted pyrazolopyrimidines: Pyrazolo-pyrimidine derivatives are described herein. The described invention also includes methods of making such derivatives as well as methods of using the same in the treatment of diseases.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B475

20070293491 - Indazole compounds and methods for inhibition of cdc7: New compounds capable of acting as CDC7 inhibitors are provided. The compounds are useful either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of CDC7 mediated diseases, such as cancer. The compounds have the Formula (I) or (II), where the values of... Agent: Chiron Corporation Intellectual Property - R440

20070293490 - Quinazoline derivatives: A quinazoline derivative of the formula (I) wherein: R1, R2, R3, R3a, R4, R5, R5a R6, R7, a, m and p are as defined in the description. Also claimed are pharmaceutical compositions containing the quinazoline derivative, the use of the quinazoline derivatives as medicaments and processes for the preparation of... Agent: Morgan Lewis & Bockius LLP

20070293492 - Quinoline tachykinin receptor antagonists: The present invention is directed to certain quinoline compounds which are useful as neurokinin-1 (NK-1) receptor antagonists, and inhibitors of tachykinin and in particular substance P. The invention is also concerned with pharmaceutical formulations comprising these compounds as active ingredients and the use of the compounds and their formulations in... Agent: Merck And Co., Inc

20070293494 - 2-anilino-4-(heterocyclic) amino-pyrimidines: The present invention relates to 2-arylamino-4-(heterocyclic)aminopyrimidines inhibitors which are inhibitors and therefore inhibit Protein Kinase C-alpha (PKC-α). The PKC-α inhibitors of the present invention are important for improving myocardial intracellular calcium cycling, resulting in improved myocardial contraction and relaxation performance and thereby slowing the progression of heart failure. The present... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20070293495 - Beta-amyloid protein production/secretion inhibitors: e

20070293493 - Oxazolidinone antibiotics and derivatives thereof:

20070293496 - Nitrogen containing heterocyclic compounds and medicines containing the same:

20070293497 - 2,3,4,6-substituted pyridyl derivative compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease: The present invention is directed to 2,3,4,6-substituted pyridyl derivative compounds which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the... Agent: Merck And Co., Inc

20070293498 - Modulators of melanocortin receptor: e

20070293499 - Intracellular kinase inhibitors: Intracellular kinase inhibitors and their therapeutic uses for patients with T cell malignancies, B cell malignancies, autoimmune disorders, and transplanted organs.... Agent: Banner & Witcoff, Ltd.

20070293500 - Quinazoline derivatives as medicaments: Quinazoline derivatives and their pharmaceutically acceptable salts are inhibitors of TGFβ activity and are used to treat conditions characterized by enhanced TGFβ activity.... Agent: Morrison & Foerster LLP

20070293501 - Thioalkeneamides as transketolase inhibitors: The present invention provides thioalkeneamides of formula (I) which are useful as transketolase inhibitors: wherein R1, R2, R3, R4, R5, R6, Ra-Rd, n and ring A are as defined herein. The present invention also provides pharmaceutical compositions comprising the compounds of formula (I). The invention provides methods for inhibiting transketolase... Agent: Ropes & Gray LLP Patent Docketing 39/361

20070293502 - Diarylmethyl piperazine derivatives, preparations thereof and uses thereof: Compounds of formula: wherein R1, R2 and R3 are as defined in the specification, as well as salts, enantiomers thereof and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain.... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20070293503 - Phenylenediamine urotensin-ii receptor antagonists and ccr-9 antagonists: The present invention relates to urotensin II receptor antagonists, CCR-9 antagonists, pharmaceutical compositions containing them and their use.... Agent: Jones Day

20070293504 - N-phenyl-2-pyrimidine-amine derivatives: The present invention relates to novel amides and a process for preparing these amides.... Agent: Novartis Corporate Intellectual Property

20070293505 - Combination preparations comprising slv308 and a dopamine agonist: e

20070293506 - Combination preparations comprising bifeprunox and a dopamine agonist:

20070293507 - Pyrazole kinase modulators and methods of use: The present invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. Compounds of the invention inhibit, regulate and/or modulate kinases. Methods of using the compounds and pharmaceutical compositions thereof to treat kinase-dependent diseases and conditions are... Agent: Mcdonnell Boehnen Hulbert @ Berghoff LLP

20070293509 - Pyrazinecarboxamide derivatives as cb1 antagonists: e

20070293508 - Crf receptor antagonists and methods relating thereto:

20070293510 - Thiadiazole compounds and use thereof:

20070293511 - Crf receptor antagonists and methods:

20070293512 - Condensed pyrimidine deriviative and xanthine oxidase inhibitor: in which R1 is a group of phenyl, naphthyl, pyridyl or the like which may have a substituent such as an alkyl group having 1-8 carbon atoms, an alkoxy group having 1-8 carbon atoms, an alkoxycarbonyl group having 2-8 carbon atoms, carboxyl, halogen, hydroxyl, nitro, or cyano; R2 is cyano,... Agent: Nixon Peabody

20070293513 - Cristalline and amorphous form of a triazolo (4,5-d) pyridimine compound: The invention provides new forms of a chemical compound of formula (I). The invention relates to forms fo a chemical compound (I), in particular to crystalline and amorphous forms, more particularly four crystalline forms and an amorphous form. The invention further relates to processes for the preparation of such forms,... Agent: Nixon & Vanderhye, PC

20070293515 - 1,3-disubstituted heteroaryl nmda/nr2b antagonists: (wherein A, B, D, P, Q, R1, R2, R3, W and Y are described herein) or pharmaceutically acceptable salts thereof, are effective as NMDA/NR2B antagonists useful for treating neurological conditions such as, for example, pain, Parkinson's disease, Alzheimer's disease, epilepsy, depression, anxiety, ischemic brain injury including stroke, and other conditions.... Agent: Merck And Co., Inc

20070293516 - Kinase antagonists: The present invention provides novel compounds that are antagonists of PI3 kinase, PI3 kinase and tryosine kinase, PI3Kinase and mTOR, or PI3Kinase, mTOR and tryosine kinase.... Agent: Paul, Hastings, Janofsky & Walker LLP

20070293514 - Triazolopyrimidines: e

20070293517 - Derivatives of chemotherapeutic agents with a formaldehyde releasing moiety: Novel conjugates of chemotherapeutic agents, which are designed so as to release formaldehyde or analogs thereof upon cleavage, processes of preparing same, pharmaceutical compositions containing same and methods utilizing same for treating medical conditions such as cancer, immune-mediated diseases, viral infections and diseases, bacterial infections and diseases, fungal infections and... Agent: Martin D. Moynihan Prtsi

20070293518 - Prolonged improvement of renal function comprising infrequent administration of an aa1ra: A method for treating a patient, comprising providing a therapeutically-effective amount of an AA1RA to the patient; and informing the patient or a medical care worker that administration of the AA1RA can provide an improvement in renal function that persists for a time period following administration of the AA1RA, and... Agent: Knobbe Martens Olson & Bear LLP

20070293519 - Analogs of thalidomide as potential angiogenesis inhibitors: A number of thalidomide metabolites having superior anti-angiogenic properties have now been isolated and identified. In addition, thalidomide analogs that mimic the effects of the isolated and identified active thalidomide metabolites, and variations of such thalidomide analogs, have been developed. Such thalidomide analog compounds show enhanced potency in the inhibition... Agent: Klarquist Sparkman, LLP

20070293520 - 2,4-pyrimidinediamine compounds and their uses: The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and prevention of diseases characterized... Agent: Rigel Pharmaceuticals Inc.

20070293521 - 2,4-pyrimidinediamine compounds and their uses: The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and prevention of diseases characterized... Agent: Rigel Pharmaceuticals Inc.

20070293522 - 2,4-pyrimidinediamine compounds and their uses: The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and prevention of diseases characterized... Agent: Rigel Pharmaceuticals Inc.

20070293523 - 2,4-pyrimidinediamine compounds and their uses: The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and prevention of diseases characterized... Agent: Rigel Pharmaceuticals Inc.

20070293524 - 2,4-pyrimidinediamine compounds and their uses: The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and prevention of diseases characterized... Agent: Rigel Pharmaceuticals Inc.

20070293525 - 2-anilino-4-aminoalkyleneaminopyrimidines: The present invention relates to 2-arylamino-4-(aminoalkylene)aminopyrimidines inhibitors which are inhibitors and therefore inhibit Protein Kinase C-alpha (PKC-α). The PKC-α inhibitors of the present invention are important for improving myocardial intracellular calcium cycling, resulting in improved myocardial contraction and relaxation performance and thereby slowing the progression of heart failure. The present... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20070293526 - Arylsulfonyl naphthalene derivatives and uses thereof: e

20070293527 - Polycyclic compounds as potent alpha2-adrenoceptor antagonists: wherein X, Z, R1 to R10, R15, R16, m, n, r and t are as defined in claim 1, or a pharmaceutically acceptable salt or ester thereof, useful as an alpha-2 antagonist. The compounds of formula I can be used for the treatment of diseases or conditions where antagonists of... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070293529 - Tetrasubstituted ureas as modulators of 11-beta hydroxyl steroid dehydrogenase type 1: The present invention relates to tetra-substituted urea compounds which are modulators of 11-β hydroxyl steroid dehydrogenase type 1 (11βHSD1), their pharmaceutical compositions, and methods of using the same.... Agent: Fish & Richardson PC

20070293528 - Tricyclic androgen receptor modulator compounds and methods: This invention relates to non-steroidal tricyclic compounds that are modulators of androgen receptors and to methods for making and using such compounds.... Agent: Fish & Richardson, PC

20070293530 - Sulfamide and sulfamate derivatives as histone deacetylase inhibitors: i

20070293531 - Muscarinic acetycholine receptor antagonists: Muscarinic Acetylcholine Receptor Antagonists and methods of using them are provided.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20070293532 - Pyrrolo [2,3-c] pyridine compound, process for producing the same, and use: s

20070293533 - Substituted 3-amino-thieno[2,3-b]pyridine-2-carboxylic acid amide compounds and processes for preparing and their uses: wherein R1 and R4 are defined herein, which are useful as inhibitors of the kinase activity of the IκB kinase (IKK) complex. The compounds are therefore useful in the treatment of IKK mediated diseases including autoimmune diseases inflammatory diseases, cardiovascular disease and cancer. Also disclosed are pharmaceutical compositions comprising these... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20070293534 - Process for the preparation of mivacurium chloride: A process for preparing the [R-[R*,R*-(E)]]-2,2′-(1,8-dioxo-4-octene-1,8-diyl) bis(oxy-3,1-propanediyl)bis(1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl) methyl]isoquinolinium) dichloride, commonly known as mivacurium chloride, useful as short-duration neuromuscular blocking agent.... Agent: Paul D. Greeley Ohlandt, Greeley, Ruggiero & Perle, L.L.P.

20070293535 - Nuclear transfer promoter for ddc42 protein and method of screening the dame: A nuclear transfer promoter for Cdc42 protein comprising an isoprenoid synthesis inhibitor and/or a geranylgeranyl transferase inhibitor such as an HMG-CoA synthase inhibitor, an HMG-CoA reductase inhibitor, an AMPK activator or a farnesyl pyrophosphoric acid synthase preparation; utilization thereof; a method therefor; a blood vessel remedy comprising the nuclear transfer... Agent: Westerman, Hattori, Daniels & Adrian, LLP

20070293536 - Salts and polymorphs of a potent antidiabetic compound: Salts and polymorphs of a compound useful in the treatment of inflammatory and metabolic conditions and diseases are provided herein. In particular, the invention provides salts and polymorphs of a compound which modulates the expression and/or function of a peroxisome proliferator-activated receptor. The salts and polymorphs are useful for the... Agent: Jones Day

20070293537 - Stable laquinimod preparations: The invention relates to a pharmaceutical composition comprising a pharmaceutically acceptable salt of N-ethyl-N-phenyl-1,2,-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, N-methylglucamine, and a pharmaceutically acceptable carrier.... Agent: Cooper & Dunham, LLP

20070293538 - Pharmaceutical composition and methods for treating neurodegenerative disorders: The invention provides compositions and methods for treating neurodegenerative disorders. The method of the invention involves administering to an individual in need of treatment a composition having an R-NSAID or a derivative thereof and a SSRI. The methods and compositions of the invention are useful for treating and preventing neurodegenerative... Agent: Myriad Genetics Inc. Intellecutal Property Department

20070293539 - Methods for the treatment of synucleinopathies: Methods are provided of treating synucleinopathies, such as Parkinson's Disease, Diffuse Lewy Body Disease and Multiple System Atrophy, comprising administering to a synucleinopathic subject a farnesyl transferase inhibitor compound.... Agent: Wolf Greenfield & Sacks, P.C.

20070293540 - Novel hydroxamates as therapeutic agents: The present invention is directed to certain hydroxamate derivatives that are useful in the treatment of hepatitis C. These compounds are also inhibitors of histone deacetylase and are therefore useful in the treatment of diseases associated with histone deacetylase activity. Pharmaceutical compositions and processes for preparing these compounds are also... Agent: Wilson Sonsini Goodrich & Rosati

20070293541 - 4-cyanopyrazole-3-carboxamide derivatives, preparation and application thereof: e

20070293542 - Selective cox-2 inhibitors: The invention features compounds that are inhibitors of COX-2 activity. Certain of the compounds are inhibitors of FAAH activity as well as COX-2 activity. The compounds include a 5-membered or 6-membered substituted or unsubstituted heteroaryl or heterocyclyl ring having one or two heteroatoms selected from the group consisting of O,... Agent: Fish & Richardson PC

20070293543 - Threshold blood omeprazole concentration is 50 ng/ml for the maintenance of intragastric ph of at least 4.0 after oral dosing with cma-omeprazole, agn 201904-z: Dosage forms of sodium {4-[5-Methoxy-2-(4-methoxy-3,5-dimethyl-pyridin-2-ylmethanesulfinyl)-benzoimidazole-1-sulfonyl]-phenoxy}-acetate, and methods of use of the dosage forms are disclosed herein.... Agent: Allergan, Inc.

20070293545 - Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists: s

20070293544 - Novel 4-arylamino pyridone derivatives as mek inhibitors for the treatment of hyper-proliferative disorders: The invention provides novel, substituted 4-arylamino pyridone compounds (formula (I)), pharmaceutically acceptable salts, solvates and prodrug compounds thereof, wherein W, R 1, R2, R9, R 10, R 11, R 12, R 13, R 14 and L are as defined in the specification. Such compounds are MEK inhibitors and useful in... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20070293546 - Preparation of rosiglitazone and its salts: The present invention relates to rosiglitazone and its pharmaceutically acceptable salts free of at least one of the process related impurities, in particular the dehydro and the succinic acid impurities of rosiglitazone, wherein said impurities are present in an amount of about 05 mg to not more than about 15... Agent: Dr. Reddy's Laboratories, Inc.

20070293547 - Compounds and compositions as lxr modulators: The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of liver X receptors (LXRs).... Agent: Genomics Institute Of The Novartis Research Foundation

20070293549 - Fungicidal compositions based on pyridylmethylbenzamide derivatives and at least one complex iii inhibiting compound: 1) Fungicidal compositions comprising: a) at least one pyridylmethylbenzamide derivative of Formula (I), in which the various radicals are as defined in the description; and b) at least one compound (II) capable of inhibiting the transport of electrons of the respiratory chain of mitochondrial ubiquinol:ferricytochrome-c oxidoreductase or complex III in... Agent: Ostrolenk Faber Gerb & Soffen

20070293548 - Inhibitors of semicarbazide-sensitive amine oxidase (ssao) and vap-1 mediated adhesion useful for treatment and prevention of diseases: Compositions and methods of using compositions for treatment of inflammatory diseases and immune disorders are provided. Allylamino compounds are disclosed which are inhibitors of semicarbazide-sensitive amine oxidase (SSAO) and/or vascular adhesion protein 1 (VAP-1). The compounds have therapeutic utility in suppressing inflammation and inflammatory responses, and in treatment of several... Agent: Morrison & Foerster LLP

20070293550 - Use of alkyl carboxylic acid amides as penetration enhancers: Use of alkyl carboxylic acid amides having formula (I): R1—CO—NR2R3, wherein R1═C3-C19-Alkyl, R2═C1-C6-alkyl and R3═H or C1-C6-alkyl, for promoting the penetration of agrochemical active substances in plants.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20070293551 - Substituted gamma lactams as therapeutic agents: e

20070293552 - Antihypertensive therapy method: Methods and therapeutic combinations are provided for lowering blood pressure in a subject exhibiting resistance to a baseline antihypertensive therapy with one or more drugs, or a subject having diabetes and/or chronic kidney disease. A method of the invention comprises administering, in some embodiments adjunctively with a modified baseline therapy,... Agent: Harness, Dickey, & Pierce, P.l.c

20070293553 - Diphenylurea derivatives useful as potassium channel activators: The present invention relates to the medical use of a certain group of diphenyl urea derivatives as potassium channel blockers for treating cardiovascular diseases, an obstructive or inflammatory airway disease, urinary incontinence, psychosis, epilepsy or pain, or for facilitating the blood-brain barrier permeability for other therapeutic substances. In other aspects... Agent: Birch Stewart Kolasch & Birch

20070293554 - Non-peptide inhibition of t-lymphocyte activation and therapies related thereto: Compounds, preparations and methods for immunosuppressive treatment of autoimmune disorders, graft rejection and/or graft/host disease. Therapeutically effective amounts of certain substituted triarylmethane compounds, such as 1-[(2-chlorophenyl)diphenylmethyl]-1H-pyrazole, are administered to mammalian patients to selectively inhibit the calcium-activated K+ channel (IKCa1) in lymphocytes, monocytes, macrophages, platelets or endothelial cells without concomitant inhibition... Agent: Stout, Uxa, Buyan & Mullins, LLP

20070293555 - Azole derivatives and pharmaceutical compositions containing them: The invention provides substituted pyrazolidinone compounds, and methods of treatment and pharmaceutical compositions that utilize or comprise one or more such compounds. Compounds of the invention are useful for a variety of therapies, including treating or preventing various cancers, inflammation, septic shock, preterm labor, infertility, pain, and ischemia, and other... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20070293556 - Prophylactic or therapeutic agent for diabetic maculopathy: wherein X represents a halogen or a hydrogen atom, R1 and R2 concurrently or differently represent a hydrogen atom or an optionally substituted C1 to C6 alkyl group, or R1 and R2, together with a nitrogen atom bound thereto and optionally another nitrogen atom or an oxygen atom, are combined... Agent: Burr & Brown

20070293557 - Anticancer compositions, and methods of making and using the same: e

20070293558 - Ophthalmic compositions for treating ocular hypertension: This invention relates to potent potassium channel blocker compounds of Formula I or a formulation thereof for the treatment of glaucoma and other conditions which leads to elevated intraoccular pressure in the eye of a patient. This invention also relates to the use of such compounds to provide a neuroprotective... Agent: Merck And Co., Inc

20070293560 - Compounds and compositions: i

20070293559 - Orally administered agent for preventing or improving dry station of skin: Orally administered agents, foods and drinks, feeds, food additives or feed additives for preventing or treating a dry state of the skin accompanied by atopic dermatitis, xeroderma, chapped hand, chapped skin and the like are provided. The present invention can provide orally administered agents, foods and drinks, feeds, food additives... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070293561 - Therapeutic compounds: a

20070293562 - Antidiabetic agent for control of diabetic hyperglycemia and diabetic complications: Described herein is a compound of Formula I, which is the metformin salt of the naturally occurring endogenous biological compound, (R)-(+) α lipoic acid, pharmaceutical compositions containing the compound of Formula I, and methods of treatment of diabetes or diabetic complications with the compound of Formula I.... Agent: Ropes & Gray LLP Patent Docketing 39/41

20070293563 - Novel agents for preventing and treating disorders connected to impaired neurotransmission: The present invention refers to coumarin ethers of the formula (I), wherein R1 is H, OH or (E)-3-methyl-but-2-enyl, R2 is selected from the group consisting of methyl, 3-(4,5-dihydro-5,5-dimethyl-4-furanon-2-yl)-2-(E/Z)-butenyl, (E/Z)-3,7-dimethylocta-2,6-dienyl, 7-hydroxy-3,7-dimethyl-2-octen-6-on-yl and (E/Z, E/Z)-1-acetyl-oxy-3,7,11,11-tetramethyl-undeca-2,7-dien-10-on-yl, R3 is H, R1 and R2O together for the group —O—C(C(═CH2)CH3)H—CH2—O— or the group —C(H)═C(H)—C(CH3)2—O— or R2O... Agent: Nixon & Vanderhye, PC

20070293564 - Dimeric compounds and their use as anti-viral agents: A method for the prevention of an orthomyxovirus or paramyxovirus infection comprising the step of administration to a subject in need thereof of an effective amount of a compound of formula (I)... Agent: Foley And Lardner LLP Suite 500

20070293565 - Ester compound and its use in pest control: m

20070293566 - Combinations of vanadium with antidiabetics for glucose metabolism disorders: Compositions and methods of using the same for the treatment of diabetes and other disorders of glucose metabolism are provided. Compositions may include an anti-diabetic agent and one or more of a bioavailable source of chromium and vanadium.... Agent: Foley Hoag, LLP Patent Group, World Trade Center West

20070293567 - Substituted biphenyl carboxylic acids and derivatives thereof: The present invention relates to compounds having the general Formula (I) with the definitions of X, Y, R1, R2, R3, R4 R9, and R10 given below, and/or a salt or ester thereof. Furthermore the invention relates to the use of said compounds for the treatment of Alzheimer's disease and their... Agent: Philip S. Johnson Johnson & Johnson

20070293568 - Neurocyte protective agent: A neurocyte protective agent that is capable of alleviating mitochondrial dysfunction and oxidative stress in neurocytes is provided. The neurocyte protective agent and the agent for protecting neurodegenerative diseases according to the present invention comprise astaxanthin and/or an ester thereof. In particular, the neurocyte protective agent of the present invention... Agent: Mcleland Patent Law Office, P.l.l.c.

20070293569 - Pentaerythritol derivatives and a method for preparation thereof, and liquid crystal base containing the same: The present invention relates to pentaerythritol derivatives represented by the following formula 1, which improve moisture retaining ability of the stratum corneum when show high moisturizing ability even in dry conditions, to a preparation method thereof, and to a liquid crystal base containing the same. (Wherein R is the same... Agent: Sughrue Mion, PLLC

20070293570 - Pharmaceutical uses for alpha2delta ligands: e

20070293571 - Adminstration of dopa precursors with sources of dopa to effectuate optimal catecholamine neurotransmitter outcomes: A method of treating neurotransmitter dysfunction in a patient by optimizing catecholamine levels by administration of L-3,4-dihydroxyphenylalanine (L-Dopa or Dopa) precurors in combination with a source of L-Dopa. The dopa precursor is preferably administered in such quantities such that the amount of dopa from the dopa precursors does not fluctuate... Agent: Patterson, Thuente, Skaar & Christensen, P.A.

20070293572 - Anti-fatigue composition: Fatigue is significantly involved in the lifestyle of people today. Although many anti-fatigue products are on market, those with definite and reliable effects are still few. Under such circumstances, the inventors of the present invention have conducted studies aiming at providing a composition which exhibits a distinctive anti-fatigue effect, and... Agent: Sughrue Mion, PLLC

20070293573 - Glu2 receptor modulators: The present invention provides for compositions and methods for modulating the GluR2 receptor. It is based, at least in part, on the discovery, by X-ray crystallography, that a known GluR2 agonist binds to the receptor in two different orientations, thereby diminishing its potency. The present invention provides for structural alternatives... Agent: Baker Botts L.L.P.

20070293574 - Cholecystokinin-1(cck1) receptor antagonists in the treatment of gastrointestinal and related disorders: Cholecystokinin-1 (CCK1) receptor antagonists and the combination of CCK1 receptor antagonists and proton pump inhibitors (PPI) for the treatment of patients suffering from gastrointestinal or related disorders that have failed to completely respond to conventional acid suppression therapy.... Agent: Sughrue Mion, PLLC

20070293575 - Compounds and methods for treatment of cancer-related anemia: The invention relates to methods and compounds for treating anemia of cancer. In particular, methods for treating anemia of cancer in a subject having cancer, and methods for increasing reticulocytes, increasing hemoglobin, increasing hematocrit, and increasing red blood cell count in subjects having anemia of cancer, wherein such subjects are... Agent: Fibrogen, Inc. Intellectual Property Department

20070293576 - Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease: In general, the invention relates to a pharmaceutical dose having R-flurbiprofen as the active ingredient that upon oral administration of a single dose to a fasting subject provides a Cmax of about 30-95 μg per mL. When the dose is administered to an individual having mild-to-moderate Alzheimer's disease (or desiring... Agent: Myriad Genetics Inc. Intellecutal Property Department

20070293577 - Hydroxycitric acid derivatives and skin external preparations using the same: Hydroxycitric acid derivatives and salts thereof are provided which are useful as active ingredients of skin external preparations and cosmetics. Also provided are processes for production of the hydroxycitric acid derivatives, and skin external preparations and cosmetics containing the hydroxycitric acid derivatives. Specific hydroxycitric acid derivatives or salts thereof are... Agent: Sughrue Mion, PLLC

20070293578 - Cathepsin cysteine protease inhibitors: This invention relates to a novel class of compounds, diagrammed below, wherein R1, R2, R3, R4, R5, R6, R7, D and n are defined therein, which are cysteine protein inhibitors, including, but not limited to, inhibitors of cathepsins K, L, S and B. These compounds are useful for treating diseases... Agent: Merck And Co., Inc

20070293582 - Epinephrine dosing regimens comprising buccal, lingual or sublingual and injectable dosage forms: The present invention relates to methods of administering a series of epinephrine doses for the treatment of allergic emergencies, including anaphylaxis, comprising buccal, lingual or sublingual epinephrine dosage forms and injectable epinephrine dosage forms. Also provided herein are kits and packaging systems useful in these methods.... Agent: Wilson Sonsini Goodrich & Rosati

20070293580 - Methods for buccal, lingual or sublingual dosing regimens of epinephrine for the treatment of allergic emergencies: The present invention relates to methods of administering dosage forms which comprise epinephrine, including buccal, lingual, sublingual or transmucosal dosage forms comprising epinephrine for treatment of allergic emergencies, including anaphylaxis. Also provided herein are kits and packaging systems useful in these methods.... Agent: Wilson Sonsini Goodrich & Rosati

20070293581 - Methods for buccal, lingual or sublingual dosing regimens of epinephrine for the treatment of allergic emergencies: The present invention relates to methods of administering dosage forms which comprise epinephrine, including buccal, lingual, sublingual or transmucosal dosage forms comprising epinephrine for treatment of allergic emergencies, including anaphylaxis. Also provided herein are kits and packaging systems useful in these methods.... Agent: Wilson Sonsini Goodrich & Rosati

20070293579 - Use of carp inhibitors for the treatment of heart diseases: The present invention relates to the novel finding that inhibition of human CARP protein or of CARP DNA/mRNA may successfully cure heart disorders, especially heart failure in humans. The invention relates, therefore, to pharmaceutical compositions containing substances, preferably of lower molecular weight, which may influence the activity of cardiac CARP.... Agent: Millen, White, Zelano & Branigan, P.C.

20070293583 - Use of low-dose ladostigil for neuroprotection: The subject invention provides a method of preventing a neurodegenerative disease in a subject or oxidative stress in the brain of a subject, comprising administering to the subject a less than cholinesterase-inhibitory amount or a less than monoamine oxidase-inhibitory amount of R(+)-6-(N-methyl,N-ethyl-carbamoyloxy)-N′-propargyl-1-aminoindan or a salt thereof effective to prevent the... Agent: Cooper & Dunham, LLP

20070293584 - Modified release formulations of a bupropion salt: The present invention relates to pharmaceutical compositions, formulations and medicaments comprising a bupropion salt, in particular, modified-release tablets comprising an effective amount of bupropion hydrobromide, and the use of the bupropion salt to prepare a medicament to treat a condition.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20070293585 - Gossypol co-crytals and the use thereof: This invention relates to compositions comprising co-crystals of (−)-gossypol with a C1-8 carboxylic acid or C1-8 sulfonic acid which are useful as inhibitors of Bcl-2 family proteins. The invention also relates to the use of co-crystals of (−)-gossypol with a C1-8 carboxylic acid or C1-8 sulfonic acid for inducing apoptosis... Agent: Casimir Jones, S.c.

20070293586 - Novel propofol composition comprising ascorbic acid or pharmaceutically acceptable salts thereof: Sterile pharmaceutical compositions for parenteral administration containing 2,6-diisopropylphenol (propofol) are described for use as anesthetics. The compositions comprise an oil-in-water emulsion of propofol additionally comprising an amount of ascorbic acid or its pharmaceutically acceptable salts thereof sufficient to prevent significant growth of microorganisms for at least 24 hours after adventitious... Agent: Taro Pharmaceuticals U.s.a., Inc. C/o Venable LLP

20070293587 - Combating sinus, throat, and blood infections with xylitol delivered in the mouth: A method of suppressing bacteria that cause infections of the throat, sinuses, heart and arteries, and joints (arthritis) by delivering xylitol in a human mouth. The method is effective with troches of pure xylitol or with xylitol chewing gum or liquid, provided sufficient quantities of xylitol are delivered. Streptococcus mutans... Agent: Graybeal, Jackson, Haley LLP

20070287661 - Compositions and methods for prevention or treatment of thrombocytopenia and methods for manufacturing said compositions: This invention teaches a composition of peptides, amino acids, and microelements derived from keratin-containing animal material for treating thrombocytopenia and a method for manufacturing thereof, comprising hydrolyzing keratin-containing animal materials, and particularly animal nails, to obtain a hydrolysate; filtering and concentrating the hydrolysate; admixing alcohol; and purifying the resultant solution.... Agent: Matthias Scholl

20070287674 - New treatment of diabetes mellitus: This invention is directed to a novel method for the treatment of diabetes mellitus (Type I, Impaired Glucose Tolerance [“IGT”] and Type II) by administering a therapeutically effective amount of one or both α-glucosidase inhibitor namely paniculoside IV and ent-16, 17-dihydroxy-(−)-kauran-19-oic acid to humans and animals.... Agent: Sarfaraz K. Niazi

20070287679 - Ornithine aminotransferase (oat): a target for anticancer drugs: Ornithine δ-aminotransferase (OAT) facilitates microtubule assembly in addition to its aminotransferase activity in mitochondria. N-terminal proteolysis of the first 17 amino acids of OAT block its transport to the mitochondria. The resultant truncated protein (OATC) forms specific complexes with mitotic spindle promoting proteins such as Eg5 and takes on a... Agent: Richard Aron Osman

20070287662 - Multi-component antioxidant compounds, pharmaceutical compositions containing same and their use for reducing or preventing oxidative stress: An antioxidant compound is disclosed. The compound is characterized by (a) a peptide including at least three amino acid residues of which at least two are cysteine residues, each having a readily oxidizable sulfhydryl group for effecting antioxidation; and at least two peptide bonds, each being cleavable by at least... Agent: Martin D. Moynihan Prtsi, Inc.

20070287660 - Novel clot-specific steptokinase proteins possessing altered plasminogen activation-characteristics and a process for the preparation of said proteins: Clot-specific streptokinase proteins possessing altered plasminogen characteristics, including enhanced fibrin selectivity. The kinetics of plasminogen activation by these proteins are distinct from those of natural streptokinase, in that there is a temporary delay or lag in the initial rate of catalytic conversion of plasminogen to plasmin. Also disclosed are processes... Agent: Sughrue Mion, PLLC

20070287663 - Glycopeptide composition with improved antibiotic activity: A glycopeptide composition with improved antibiotic activity is disclosed, along with a method of preparing such a composition and a pharmaceutical composition made therefrom.... Agent: Cantor Colburn, LLP

20070287664 - Combinations of hcv protease inhibitor(s) and cyp3a4 inhibitor(s), and methods of treatment related thereto: Disclosed are medicaments, pharmaceutical compositions, pharmaceutical kits, and methods based on combinations comprising, separately or together: (a) a CYP3A4 inhibitor; and (b) a HCV protease inhibitor; for concurrent or consecutive administration in treating a human subject infected with HCV.... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20070287665 - Urotensin-ii agonists and antagonists: The present invention features a novel class of cyclic polypeptides that have U-II antagonist and agonist activity. The invention also features methods for treating physiological or psychological conditions characterized by an excess or an under expression of Urotensin-II.... Agent: Alan F. Feeney, Esq. Biomeasure, Incorporated

20070287667 - Anti-hepatitis a virus antibodies: Chimpanzee monoclonal antibodies and antigen binding fragments including a γ1-chain CDR3 region that bind hepatitis A virus (HAV) antigen are disclosed herein. The antibodies neutralize HAV. Also disclosed are methods for using these antibodies and antigen binding fragments in the detection of hepatitis A virus, the inhibition of infection of... Agent: Klarquist Sparkman, LLP

20070287669 - Combined use of derivatives of glp-1 analogs and ppar ligands: The present invention provides methods and compositions for treatment and/or prevention of type 1 and type 2 diabetes, dyslipdemia, impaired glucose tolerance, insulin resistance, obesity, and beta-cell apoptosis, as well as methods for increasing the size and number of beta-cells in a subject and/or stimulating beta-cell proliferation, which comprise administering... Agent: Novo Nordisk, Inc. Patent Department

20070287668 - Methods, kits, and antibodies for detecting parathyroid hormone: The present invention relates to novel methods and compositions useful for detecting whole parathyroid hormone at a physiological level and parathyroid fragments in a mammalian sample. Such detections may be useful to different parathyroid diseases or disorders in a subject, such as hyperparathyroidism and related bone diseases, from normal or... Agent: Morrison & Foerster LLP

20070287666 - Modulator of gamma-secretase: The invention relates to modulators of γ-secretase and to methods and uses related thereto. In one embodiment the modulators do not modulate ε-secretase activity. In another embodiment the invention relates to presenilin complex component. In one embodiment the presenilin component is TMP21.... Agent: Mccarthy Tetrault LLP

20070287670 - Human glucagon-like peptide-1 mimics and their use in the treatment of diabetes and related conditions: The present invention provides novel human glucagon-like peptide-1 (GLP-1) peptide mimics that mimic the biological activity of the native GLP-1 peptide and thus are useful for the treatment or prevention of diseases or disorders associated with GLP activity. Further, the present invention provides novel, chemically modified peptides that not only... Agent: Louis J. Wille Bristol-myers Squibb Company

20070287671 - Compositions and methods for promoting myocardial and peripheral angiogenesis: Methods, compositions and devices are disclosed for use in growing new blood vessels to restore or improve blood flow to ischemic tissues and organs of the body. Compositions comprising IGD peptides, particularly GGIGDGG, are able to induce migration in human endothelial cells and promote vessel formation in an in vitro... Agent: Williams, Morgan & Amerson

20070287672 - Macromolecular gsh-activiated glyoxylase i inhibitors: This invention relates to macromolecular prodrugs having antitumor activity when activated by GSH, and methods for synthesizing and administering these to patients. More particularly, this invention relates to, inter alia, the synthesis and use of polyacrylamide carriers to target anticancer prodrugs to tumors, and to release active antitumor agents selectively... Agent: Sughrue Mion, PLLC

20070287673 - Monosaccharide derivatives: The present invention relates to monosaccharide derivatives as anti-inflammatory agents. The compounds disclosed herein can be useful for inhibition and prevention of inflammation and associated pathologies including inflammatory and autoimmune diseases such as bronchial asthma, rheumatoid arthritis, type I diabetes, multiple sclerosis, allograft rejection, psoriasis, inflammatory bowel disease, ulcerative colitis,... Agent: Jayadeep R. Deshmukh, Esq. Ranbaxy Inc.

20070287675 - Enhanced delivery of drug compositions to treat life threatening infections: Inhalable compositions are described. The inhalable compositions comprise one or more respirable aggregates, the respirable aggregates comprising one or more poorly water soluble active agents, wherein at least one of the active agents reaches a maximum lung concentration (Cmax) of at least about 0.25 μg/gram of lung tissue and remains... Agent: The Dow Chemical Company

20070287676 - Diagnosis and treatment of endometriosis: Disclosed here are simple, non-invasive screening methods for diagnosing endometriosis, in particular, the type that is resistant to conventional progestin and progesterone therapy. Biomarkers for identifying subjects with endometriosis are disclosed. Alternative therapeutic methods with reduced side effects and compositions for treating endometriosis are also disclosed.... Agent: Quarles & Brady LLP

20070287678 - Anti-aging micrornas: Methods and compositions for modulating aging genes or their targets for the treatment or prevention of senescence or symptoms thereof have been developed based on the discovery of naturally occurring inhibitory nucleic acids, in particular lin-4 miRNA, that downregulate genes involved in senescence, lifespan, or age-related disorders. Representative aging genes... Agent: Patrea L. Pabst Pabst Patent Group LLP

20070287680 - Combined active and passive targeting of biologically active agents: Disclosed is a conjugate comprising a biologically active agent (drug) linked to a subcellular targeting moiety that targets a drug specifically to the nucleus. Targeting is achieved by attaching a steroid hormone (or an analog) to the drug. The steroid hormone attached to the drug binds its corresponding receptor, the... Agent: Needle & Rosenberg, P.C.

20070287677 - Rad51 expression inhibitors, pharmaceutical agents containing the inhibitors as active ingredients, and uses thereof: A double stranded RNA having a specific nucleotide sequence is useful for treating cellular proliferative disorders. The double stranded RNA acts as siRNA against the Rad51 gene. The double stranded RNA of the present invention inhibits cellular proliferation itself. In addition, co-administration of the double stranded RNA with a chemotherapeutic... Agent: Townsend And Townsend And Crew, LLP

20070287681 - Sirna-hydrophilic polymer conjugates for intracellular delivery of sirna and method thereof: The present invention is related to hybrid conjugates formed by covalently bonding siRNA (small interfering RNA) molecules to hydrophilic polymers for improving stability of the siRNA molecules effective for delivering the siRNA in vivo, and polyelectrolyte complex micelles formed by ionic interactions between the conjugates and multifunctional cationic compounds. The... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20070287682 - Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor: A method for the direct treatment towards the specific sites of a disease is disclosed. This method is based on the delivery of proteins by catheterization to discrete blood vessel segments using genetically modified or normal cells or other vector systems. Endothelial cells expressing recombinant therapeutic agent or diagnostic proteins... Agent: Brinks Hofer Gilson & Lione

20070287683 - Low molecular weight heparin composition and uses thereof: Preparations of low molecular weight heparins (LMWHs) having improved properties, e.g., properties that provide a clinical advantage, are provided herein. Methods of making and using such preparations as well as methods of analyzing starting materials, processing, intermediates and final products in the production of such LMWH preparations are provided.... Agent: Fish & Richardson PC

20070287684 - Methods and compositions for treating trauma-hemorrhage using estrogen and derivatives thereof: Disclosed are methods and materials for treating or preventing complications due to traumatic injuries using estrogen or derivatives thereof.... Agent: Needle & Rosenberg, P.C.

20070287685 - Medicinal composition containing fbpase inhibitor: A pharmaceutical composition containing an FBPase inhibitor and an insulin sensitizer which is 5-[4-(6-methoxy-1-methyl-1H-benzimidazol-2-ylmethoxy)benzyl]thiazolidine-2,4-dione or a pharmacologically acceptable salt thereof; and a method for preventing or treating diabetes mellitus by administering the composition to a human.... Agent: Frishauf, Holtz, Goodman & Chick, PC

20070287686 - Substance for dyeing keratinic fibers: p

20070287687 - Method for removing debris from tooth and bone surfaces using irrigation solution: Methods for removing debris and bacteria from tooth and orthopedic surfaces using irrigation solutions are provided. The solution includes disinfectant, surfactant, and organic acid components. Disinfectants such as tetracycline and doxycycline compounds can be used. Suitable surfactants include cocamidopropyl betaine compounds and polyoxypropylene-polyoxyethylene copolymers. The solution is particularly suitable for... Agent: Dentsply International Inc

20070287688 - Pharmaceutical compositions for topical application: Compounds of Formula I are useful as skin penetration enhancing agents: (I) wherein: R represents a linear, saturated or unsaturated, substituted or unsubstituted hydrocarbyl radical; and X represents a —(CO)O—, —O(CO)—, C═O, CONH, O, NHCONH, S, or S═O radical. Compositions and methods using these compounds are also described.... Agent: Nutter Mcclennen & Fish LLP

20070287690 - Compositions and methods comprising a thiazide diuretic and a mineralocorticoid inhibitor: The invention relates to low dose combinations of a thiazide diuretic and a mineralocorticoid inhibitor and methods for the treatment of hypertension and related disorders. Methods and compositions for administering a thiazide diuretic, such as chlorthalidone, and an mineralocorticoid inhibitor such as spironolactone or eplerenone in a dose range of... Agent: Accu-break Technologies, Inc.

20070287691 - Method for activating the lipid catabolic metabolism in enteric epithelium and improving the lipid metabolism in enteric epithelium: Disclosed are a method for activating lipid metabolism in the small intestine epithelium and also a method for promoting accumulation of fatty acids into the small intestine epithelium, each of which features administering an effective amount of a diacylglycerol. Also disclosed are methods for improving various symptoms in diabetes, which... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20070287689 - Therapeutic and/or preventive agents for chronic skin diseases: The present invention provides: a therapeutic and/or preventive agent for chronic skin diseases which comprises (a) a phosphodiesterase (PDE)-IV inhibitor or a pharmaceutically acceptable salt thereof and (b) a steroid agent as active ingredients; a therapeutic and/or preventive agent for chronic skin diseases to be administered simultaneously or separately with... Agent: Fitzpatrick Cella Harper & Scinto

20070287692 - Aspartyl protease inhibitors: Also disclosed is the method of inhibiting aspartyl protease, and in particular, the methods of treating cardiovascular diseases, cognitive and neurodegenerative diseases. Also disclosed are methods of treating cognitive or neurodegenerative diseases using the compounds of formula I in combination with a cholinesterase inhibitor or a muscarinic m1 agonist or... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20070287693 - Benzamide derivatives that act upon the glucokinase enzyme: wherein R1 is hydroxymethyl; R2 is selected from —C(O)NR4R5, SO2NR4R5, S(O)pR4 and HET-2; HET-1 is a 5- or 6-membered, optionally substituted C-linked heteroaryl ring; HET-2 is a 4-, 5- or 6-membered, C- or N-linked optionally substituted hererocyclyl ring; R3 is selected from halo, fluoromethyl, difluoromethyl, trifluoromethyl, methyl, methoxy and cyano;... Agent: Morgan Lewis & Bockius LLP

20070287694 - Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors: The invention encompasses compounds as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.... Agent: Louis J. Wille Bristol-myers Squibb Company

20070287695 - Novel compounds: e

20070287696 - Cgrp receptor antagonists: (where variables R1, R2, R3, R4, A, B, D, G, J, Q, T, W, X and Y are as defined herein) useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, pharmaceutical compositions comprising these compounds, use of these... Agent: Merck And Co., Inc

20070287697 - Cgrp receptor antagonists: Compounds of Formula (I) and Formula (II) (where variables R1, R2, R4, A, B, W, X, Y and Z are as defined herein) useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster... Agent: Merck And Co., Inc

20070287698 - Tetrahydrobenzo(d)azepin-2-one derivatives and the use thereof for treating cardiovascular diseases: The present application relates to novel tetrahydrobenzo[d]azepin-2-one derivatives, processes for their preparation, their use for the treatment and/or prophylaxis of diseases, and their use for producing medicaments for the treatment and/or prophylaxis of diseases, preferably for the treatment and/or prevention of cardiovascular disorders, especially of dyslipidaemias, arteriosclerosis, restenosis and ischaemias.... Agent: Jeffrey M. Greenman

20070287699 - Antiviral agents: Compounds are provided having utility for the treatment of viral infections, particularly HCV.... Agent: Townsend And Townsend And Crew, LLP

20070287700 - Polycyclic agents for the treatment of respiratory syncytial virus infections: Compounds of formula (I), and their use as in the treatment of infections involving viruses of the Pneumovirinae sub-family (RSV) are disclosed. In the formula ring (A) may be phenyl, pyridyl etc., (B-C) may be CH2—CH2etc., (R1) may be phenyl and substituted forms thereof, (R2) may be assorted substituents.... Agent: Jones Day

20070287701 - Antibacterial agents: Naphthalene, quinoline, quinoxaline and naphthyridine derivatives useful in the treatment of bacterial infections in mammals, particularly humans, are disclosed herein.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20070287702 - Thioridazine and derivatives thereof for reversing anti-microbial drug-resistance: The present invention relates to compositions comprising thioridazine, and derivatives thereof, together with antibacterials. These compositions have been found greatly enhance the activity of many classes of antibacterials, allowing the antibacterials to be administered at significantly lower doses. The thioridazine and the antibacterial act synergistically by pacifying the bacteria to... Agent: Knobbe Martens Olson & Bear LLP

20070287703 - Fused pyrimidones useful in the treatment and the prevention of cancer: Compounds which possess Eg5 inhibitory activity and are useful for their anti-cell-proliferation (such as anti-cancer) activity and thus in methods of treatment of the human or animal body are described.... Agent: Astrazeneca R&d Boston

20070287704 - Substituted pteridines: The invention relates to new pteridines which are suitable for treating respiratory or gastrointestinal complaints or diseases, inflammatory diseases of the joints, skin or eyes, diseases of the peripheral or central nervous system and cancers. This invention also relates to pharmaceutical compositions containing these compounds.... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20070287705 - Crf receptor antagonists and methods relating thereto: CRF receptor antagonists are disclosed which have utility in the treatment of a variety of disorders, including the treatment of disorders manifesting hypersecretion of CRF in a warm blooded animals, such as stroke. The CRF receptor antagonists of this invention have the following structure (I), including stereoisomers, prodrugs and pharmaceutically... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20070287706 - Certain substituted quinolones, compositions, and uses thereof: Certain quinolone-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, methods of using compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions comprising compounds exhibiting ATP-utilizing enzyme inhibitory activity, are disclosed.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070287707 - Phosphodiesterase 10 inhibitors: The present invention if directed to certain cinnoline compounds that are PDE10 inhibitors, pharmaceutical compounds containing the same and processes for preparing the same. The invention is also directed to methods of treating diseases mediated by PDE10 enzyme such as obesity, non-insulin dependent diabetes, schizophrenia or bipolar disorder, obsessive-compulsive disorder,... Agent: Jones Day

20070287708 - Substituted 3-cyanopyridines as protein kinase inhibitors: and their pharmaceutically acceptable salts, hydrates, and esters, wherein R1, R2, and X are as defined herein. The present teachings also provide methods of making the compounds of formula I, and methods of treating autoimmune and inflammatory diseases by administering a therapeutically effective amount of a compound or compounds of... Agent: Kirkpatrick & Lockhart Preston Gates Ellis LLP (formerly Kirkpatrick&lockhart Nicholson Graham)

20070287709 - Novel arylamino n-heteraryls as mek inhibitors: d

20070287710 - Sulfonamide compound:

20070287711 - Fused ring heterocycle kinase modulators: The present invention provides novel fused ring heterocycle kinase modulators and methods of using the novel fused ring heterocycle kinase modulators to treat diseases mediated by kinase activity.... Agent: Townsend And Townsend And Crew, LLP

20070287712 - Piperazine enamines as antiviral agents: This disclosure provides compounds having drug and bio-affecting properties, their pharmaceutical compositions and method of use. In particular, the disclosure is concerned with indole and azaindole piperazine enamine derivatives that possess unique antiviral activity. More particularly, the present disclosure relates to compounds useful for the treatment of HIV and AIDS.... Agent: Louis J. Wille Bristol-myers Squibb Company

20070287713 - Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method: i

20070287714 - Warming and nonirritating lubricant compositions and method of comparing irritation: This invention relates to substantially anhydrous warming, non-toxic and nonirritating lubricating compositions containing polyhydric alcohols, a gelling agent and alternatively a pH adjusting agent for treating fungal and bacterial infections. The invention also relates to methods of using such compositions for warming, lubrication, administration of active ingredients and for preventing... Agent: Philip S. Johnson Johnson & Johnson

20070287715 - Indoles useful in the treatment of inflammation: There is provided a compound of formula: (I), wherein X, R1, R2, R3, R4, R5 and R6 have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful in the treatment of diseases in which inhibition of the activity of microsomal prostaglandin E synthase-1 is desired and/or... Agent: Morgan Lewis & Bockius LLP

20070287716 - Pyrimidine and quinoline potentiators of metabotropic glutamate receptors: The present invention is directed to compounds which are potentiators of metabotropic glutamate receptors, including the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also directed... Agent: Merck And Co., Inc

20070287717 - Thienopyrimidines useful as modulators of ion channels: The present invention relates to compounds useful as inhibitors of ion channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.... Agent: Vertex Pharmaceuticals Inc.

20070287718 - Methods for the treatment of multiple myeloma using roscovitine: The present invention relates to the use of roscovitine, or a pharmaceutically acceptable salt thereof, in the preparation of a medicament for treating multiple myeloma.... Agent: Lahive & Cockfield, LLP

20070287719 - Salts, prodrugs and formulations of 1-[5-(4-amino-7-isopropyl-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-2-methoxy-phenyl]-3-(2,4-dichloro-phenyl)-urea: e

20070287720 - Method of fungal pathogen control in grass or turf: This invention relates to a method of controlling fungal organisms in turfgrass with imidacloprid and optionally one or more other fungicides.... Agent: Bayer Cropscience Lp

20070287721 - Pyrazolopyridinyl pyridine: i

20070287722 - Drop preparations comprising dimetindene: The invention relates to orally administered drops comprising the pharmaceutically active substance dimetindene, which drops are sorbitol-free and ethanol-free and characterized by special, very beneficial properties regarding physical and chemical stability, organoleptic properties as well as suitability for children.... Agent: Novartis Corporate Intellectual Property

20070287723 - 2-alkyl/aryl sulphonyl-1,2,3,4-tetrahydro-9h-pyrido (3,4-b) indole-3-carboxylic acid esters/amides useful as antithrombotic agents: e

20070287725 - Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and method: Imidazo ring compounds, (e.g. imidazo[4,5-c]pyridine, imidazo[4,5-c]quinoline, 6,7,8,9-tetrahydro imidazo[4,5-c]quinoline, and imidazo[4,5-c]naphthyridine compounds) having an isoxazole, dihydroisoxazole, or oxadiazole substituent at the 1-position, pharmaceutical compositions containing the compounds, intermediates, and methods of making and methods of use of these compounds as immunomodulators, for modulating cytokine biosynthesis in animals and in the treatment... Agent: 3m Innovative Properties Company

20070287724 - Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines: Imidazo-quinoline, -pyridine, and -naphthyridine ring systems (particularly quinolines, tetrahydroquinolines, pyridines, 1,5-naphthyridines, 1,5-tetrahydronaphthyridines) substituted at the 1-position with a cyclic substituent, pharmaceutical compositions containing the compounds, and methods of use of these compounds as immunomodulators, for inducing cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic... Agent: 3m Innovative Properties Company

20070287726 - 5-substituted 1h-pyrrolo [3,2-b] pyridines: i

20070287727 - Anti-nicotine treatment: A method is described for treatment of nicotine dependency and cessation or reduction of tobacco use in humans which combines pharmacotherapy designed to ameliorate the initial withdrawal symptoms followed by behavioral modification intended to minimize the relapse rate. Pharmacotherapy consists of the use of anticholinergic agents, which facilitate a smooth... Agent: John S. Pratt, Esq Kilpatrick Stockton, LLP

20070287728 - Novel naphthyl substituted azabicyclo derivatives and their use as monomine neurotransmitter re-uptake inhibitors: This invention relates to novel naphthyl substituted azabicyclo derivatives useful as monoamine neurotransmitter re-uptake inhibitors. In other aspects the invention relates to the use of these compounds in a method for therapy and to pharmaceutical compositions comprising the compounds of the invention.... Agent: Birch Stewart Kolasch & Birch

20070287729 - Aqueous ophthalmic suspension of crystalline rebamipide: The invention provides an ophthalmic product containing rebamipide, which has a transparency enough to be agreeable feeling on using it and has neutral to weakly acidic pH not to injury of the keratoconjunctiva of a patient suffering from dry eye. An aqueous suspension of crystalline rebamipide which has an improved... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070287730 - Alkene piperidine derivatives as antiviral agents: This disclosure provides compounds having drug and bio-affecting properties, their pharmaceutical compositions and method of use. In particular, the disclosure is concerned with alkene piperidine derivatives that possess unique antiviral activity. More particularly, the present disclosure relates to compounds useful for the treatment of HIV and AIDS.... Agent: Louis J. Wille Bristol-myers Squibb Company

20070287731 - Oxadiazoline ligands for modulating the expression of exogenous genes via an ecdysone receptor complex: The present invention relates to non-steroidal ligands for use in nuclear receptor-based inducible gene expression system, and a method to modulate exogenous gene expression in which an ecdysone receptor complex comprising: a DNA binding domain; a ligand binding domain; a transactivation domain; and a ligand is contacted with a DNA... Agent: Sughrue Mion, PLLC

20070287732 - Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists: This invention generally relates to derivatives of substituted azabicyclo hexanes of formula I. The compounds of this invention can function as muscarinic receptor antagonists, and can be used for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. The invention also relates to... Agent: Ranbaxy Inc.

20070287733 - Method of treating skin diseases: Acetylcholinesterase inhibitors, such as galantamine or donepezil, have been found to be useful in the topical treatment of skin diseases and skin problems.... Agent: Carella, Byrne, Bain, Gilfillan, Cecchi, Stewart & Olstein

20070287734 - Preparation and utility of substituted pyrazole compounds with cannabinoid receptor activity: The present disclosure is directed to modulators of CB-1 type receptors and pharmaceutically acceptable salts and prodrugs thereof, the chemical synthesis thereof, and the medical use of such compounds for the treatment and/or management of the severity and duration of obesity, metabolic syndrome, dyslipidemia, glucose imbalance, the inability to maintain... Agent: Wilson Sonsini Goodrich & Rosati

20070287735 - Chemicals, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases: Methods of using di, tri, and tetracyclic acylhydrazide derivatives and analogs, as well as pharmaceutical compositions containing the same, for the treatment or prophylaxis of viral infections and diseases associated therewith, particularly those viral infections and associated diseases cased by the orthopoxvirus.... Agent: Bingham Mccutchen LLP

20070287736 - Diphenyl substituted alkanes as flap inhibitors: t

20070287737 - Novel heteroaryl-substituted arylaminopyridine derivatives as mek inhibitors:

20070287738 - Substituted cyanopyridines as protein kinase inhibitors: and their pharmaceutically acceptable salts, hydrates, and esters, wherein R1, R2, and X are as defined herein. The present teachings also provide methods of making the compounds of formula I, and methods of treating autoimmune and inflammatory diseases by administering a therapeutically effective amount of a compound or compounds of... Agent: Kirkpatrick & Lockhart Preston Gates Ellis LLP (formerly Kirkpatrick&lockhart Nicholson Graham)

20070287739 - Aryl-4-ethynyl-isoxazole derivatives: d

20070287740 - Compositions and methods of treating middle-of-the night insomnia: The present invention provides compositions and methods for treating middle-of-the-night insomnia without residual sedative effects upon awakening by administering low doses (about 5 mg or less) of zolpidem or a salt thereof.... Agent: O'melveny & Myers LLP

20070287741 - Compositions and methods for preventing or reducing postoperative ileus and gastric stasis in mammals: Disclosed are compositions and methods for preventing or reducing postoperative ileus and gastric stasis. Such compositions include a combination of a carrier component and a bioactive component which acts to prevent or reduce post-poperative ileus. Such methods include administering atherapeutically effective amount of the composition directly to the serosal surfaces... Agent: Philip S. Johnson Johnson & Johnson

20070287743 - Adamantyl pyrrolidin-2-one derivatives as 11-beta hydroxtsteroid dehydrogenase inhibitors: s

20070287742 - Subsitituted gamma lactams as therapeutic agents:

20070287744 - N-[(4,5-diphenyl-2-thienyl)methyl]sulfonamide derivatives, preparation thereof and their therapeutic application:

20070287745 - Laulimalide analogs and uses thereof: and pharmaceutically acceptable derivatives thereof, wherein R1-R10, q, t, X0, X1, A, B, D, E, G, J, K, L, M and Z are as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of disorders associated... Agent: Myers Bigel Sibley & Sajovec

20070287746 - Use of anti-oxidant compounds for muscle recovery: The present invention describes the use of a composition comprising a compound according to formula (1) to retain or restore muscle health: formula (1) wherein: R can be H, OH or CH3O; R1 can be H, (CH2)nOR2 wherein: n is 1, 2 or 3 R2 is H, COCH3 or formula... Agent: Nixon & Vanderhye, PC

20070287747 - Process for preparing metal salts of unsaturated, short-chain carboxylic acids and use thereof: The present invention relates to the use of metal compounds of unsaturated, short-chain carboxylic acids. The invention also relates to a method for preparing metal compounds of unsaturated, short-chain carboxylic acids by reaction of said acids with a metal alcoholate.... Agent: Browning Bushman

20070287748 - Optical resolution of-3-carbamoylmethyl-5-methyl hexanoic acid: The invention relates to pure (R)—CMH and to the optical resolution of CMH-racemate, a key intermediate in the synthesis of (S)-Pregabalin. The invention also relates to the process for optically purifying (R)—CMH and to the process for isolating (S)—CMH from the mother liquor.... Agent: Kenyon & Kenyon LLP

20070287749 - Bromfenac ophthalmic formulations and methods of use: The present invention discloses a stability enhanced aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid or its pharmacologically acceptable salt or a hydrate thereof, an alkyl aryl polyether alcohol type polymer such as tyloxapol, or a polyethylene glycol fatty acid ester such as polyethylene glycol monostearate. The present invention further discloses new... Agent: Townsend And Townsend And Crew, LLP

20070287750 - Polycationic sulfonamides and use thereof: Certain lipophilic polycationic sulfonamides are provided and are useful for treating various diseases or conditions and particularly sepsis.... Agent: Connolly Bove Lodge & Hutz LLP

20070287751 - Opioid receptor antagonists: r

20070287752 - Ophthalmic compositions comprising a branched, glycerol compound: An aqueous ophthalmic composition comprising a branched glycerol compound selected from the group consisting of a branched, glycerol monoalkyl ether, a branched, glycerol monoalkyl amine, a branched, glycerol monoalkyl sulfide, or any mixture thereof, present in a total amount of from 0.05 ppm to 1,000 ppm; a cationic antimicrobial component,... Agent: Joseph Barrera Bausch & Lomb Incorporated

20070287753 - Intranasal administration of ketamine to treat depression: Methods and compositions for the treatment of treatment-resistant depression are described. More specifically, the invention demonstrates that intranasal administration of ketamine is effective to ameliorate the symptoms of depression in a patient who has not responded to an adequate trial of one antidepressant in the current episode and has recurrent... Agent: Marshall, Gerstein & Borun LLP

20070287754 - Cycloalkyl substituted polyamines for cancer therapy and methods of synthesis therefor: Conformationally restricted polyamine compounds useful in treatment of cancer and other diseases marked by abnormal cell proliferation are disclosed. Improved methods of synthesizing such compounds are also disclosed. In one method of the invention, a carbene-bearing or carbene equivalent-bearing compound is reacted with the double bond of an alkene compound... Agent: Morrison & Foerster LLP

20070287755 - Orally administered compound for preventing neonatal hemorrhages, in a tardy form, caused by a k-vitamin dificiency: The present invention relates to an orally administered compound, for preventing neonatal hemorrhages, in a tardy form, caused by a K-vitamin deficiency, comprising K1 vitamin, in an oil solution, to be administered in daily microdoses.... Agent: Pearne & Gordon LLP

20070287756 - Methods and compositions for preserving the viability of photoreceptor cells: Provided are methods and compositions for maintaining the viability of photoreceptor cells following retinal detachment. The viability of photoreceptor cells can be preserved by administering a neuroprotective agent, for example, a substance capable of suppressing endogenous MCP-1, a MCP-1 antagonist, a substance capable of suppressing endogenous TNF-alpha, a TNF-alpha antagonist,... Agent: Goodwin Procter LLP Patent Administrator

20070281882 - Combination of insulin and ascorbate to enhance wound healing: Provided is a method of stimulating collagen synthesis and proteoglycan (lumican and keratocan) accumulation. Collagenase isolated keratocytes were cultured with or without insulin with or without ascorbate. Insulin stimulates the synthesis of collagen but does not affect the accumulation of lumican and keratocan. Insulin plus ascorbate, however, stimulates the synthesis... Agent: Smith Hopen, Pa

20070281883 - Development of follicle stimulating hormone agonists and antagonists in fish: The invention provides recombinant forms of piscine follicle-stimulating hormone (FSH) with characteristic intramolecular disulfide bonds and modified glycosylation patterns in the β-subunit that enhance the stability and metabolic activity of the hormone. Also provided are recombinant materials to produce the FSH β and glycoprotein α-subunits singly or in combination to... Agent: Dr. Mark M. Friedman C/o Bill Polkinghorn - Discovery Dispatch

20070281884 - Macrocyclic oximyl hepatitis c protease inhibitors: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned... Agent: Elmore Patent Law Group, PC

20070281894 - Preparation and utility of substituted erythromycin analogs: The present disclosure is directed to novel macrolide antibiotics of Formula 1 and pharmaceutically acceptable salts and prodrugs thereof; and the chemical syntheses and medical uses of these novel macrolide antibiotics for the treatment and/or management of infections caused by various aerobic and anaerobic gram-positive and gram-negative microorganisms as well... Agent: Wilson Sonsini Goodrich & Rosati

20070281900 - Compositions and methods for lipid and polypeptide based sirna intracellular delivery: A composition of an interfering RNA comprising a double-stranded RNA (dsRNA) molecule having a double-stranded region of from about 15 to about 40 base pairs, a peptide having a hydrophobic region and a cationic region, and a non-cationic phospholipid, and uses thereof.... Agent: Nastech Pharmaceutical Company Inc

20070281904 - Chitosan-derivative compounds and methods of controlling microbial populations: The present invention is directed to chitosan-derivative compounds and structures, methods of making chitosan-derivative compounds and methods for controlling, inhibiting and enhancing microbial populations in a variety of environments. The present invention is also directed to the control, inhibition and enhancement of microbial populations in animals, particularly humans. The microbial... Agent: Ms. Abanti Bhattacharyya, Esq. Bartunek & Bhattacharyya, Ltd.

20070281909 - Creatine phosphate prodrugs, compositions and uses thereof: Membrane permeable prodrugs of creatine phosphate, pharmaceutical compositions comprising membrane permeable prodrugs of creatine phosphate, and methods of treating diseases such as ischemia, heart failure, and neurodegenerative disorders comprising administering prodrugs of creatine phosphate or pharmaceutical compositions thereof are disclosed.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070281881 - Methods and compositions comprising non-peptide small molecules that solubilize beta amyloid peptide fiber: The present invention comprises novel compositions and methods for the treatment of neurological diseases associated with beta amyloid peptide. In particular, the present invention is directed to Aβ fiber solubilization, for the treatment of amyloid-associated diseases such as Alzheimer's disease, and is described herein as being achieved by using small... Agent: John S. Pratt, Esq Kilpatrick Stockton, LLP

20070281885 - Macrocylic oximyl hepatitis c protease inhibitors: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned... Agent: Elmore Patent Law Group, PC

20070281890 - Fibroblast growth factor-13: The present invention relates to a novel FGF-13 protein which is a member of the fibroblast growth factor (FGF) family. In particular, isolated nucleic acid molecules are provided encoding the human FGF-13 protein. FGF-13 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same.... Agent: Human Genome Sciences Inc. Intellectual Property Dept.

20070281888 - Gene promoting vascular endothelial cell growth: It is intended to provide a novel polypeptide having an activity of growing vascular endothelial cells, an activity of promoting transcription form c-fos promoter, an activity of promoting transciption from VEGF promoter and/or an angiogenic activity; a polynucleotide encoding this polypeptide; the above polypeptide and/or a pharmaceutical composition containing the... Agent: Mintz Levin Cohn Ferris Glovsky & Popeo

20070281887 - Isoforms of brain natriuretic peptide: Methods and materials for diagnosing and treating heart conditions (e.g., heart failure) and kidney conditions (e.g., kidney failure) are described.... Agent: Fish & Richardson P.C.

20070281889 - Parathyroid hormone receptor activation and stem and progenitor cell expansion: The invention relates to methods for manipulating hematopoietic stem or progenitor cells, mesenchymal stem cells, epithelial stem cells, neural stem cells and related products through activation of the PTH/PTHrP receptor in neighboring cells.... Agent: Edwards Angell Palmer & Dodge LLP

20070281886 - Retinal pigmented epithelium derived neurotrophic factor: The present invention relates to a purified retinal pigmented epithelium derived neurotrophic factor composition and a method for purifying such a retinal pigmented epithelium neurotrophic factor. The present invention also relates to a recombinant DNA molecule comprising a gene encoding a retinal pigmented epithelium derived neurotrophic factor having the DNA... Agent: Woodcock Washburn LLP

20070281892 - Dopaminergic mimetics: A method is described for providing acute symptomatic relief to a subject with Parkinson's Disease (PD) or other CNS disorders resulting from dopamine deficiency in the brain comprising administering to said subject an amount of ketogenic material sufficient to produce a ketosis in the subject sufficient to provide therapeutic benefit... Agent: Nixon & Vanderhye, PC

20070281891 - Lock solution for medical devices: The invention relates to a lock solution for medical devices comprising carbohydrates and/or glucose degradation products as antimicrobial agent(s).... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070281893 - Polysulfated glycosides and salts thereof: The invention relates to polysulfated glycosides of formula (I), the pharmaceutically acceptable salts thereof, as well as the pharmaceutical compositions containing these compounds as active ingredients. Furthermore the invention provides a method of preventing, treating or alleviating the symptoms of acute and chronic inflammatory disorders of the airways of mammals—including... Agent: Lerner, David, Littenberg, Krumholz & Mentlik

20070281899 - Compositions and methods for inhibiting expression of eg5 gene: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the Eg5 gene (Eg5 gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part... Agent: Fish & Richardson PC

20070281897 - Method for stimulating the immune, inflammatory or neuroprotective response: Cycic di-GMP, or a cyclic dinucleotide analogue thereof that has the same effect as cyclic di-GMP, stimulates or enhances immune or inflammatory response in a patient or enhances the immune response to a vaccine by serving as an adjuvant. Cyclic di-GMP, or a cyclic dinucleotide analogue thereof, also has neuroprotective... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20070281895 - Molecular marker: A diagnostic method is disclosed which can be used to predict the risk of cancer in particular breast cancer. The method comprises: (i) isolating a biological sample from a patient; and (ii) detecting the presence or expression of the gene comprised within the sequence identified herein as SEQ ID No.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20070281896 - Novel compositions and methods in cancer: The present invention relates to novel sequences for use in detection, diagnosis and treatment of cancers, especially lymphomas. The invention provides cancer-associated (CA) polynucleotide sequences whose expression is associated with cancer. The present invention provides CA polypeptides associated with cancer that are present on the cell surface and present novel... Agent: Novartis Vaccines And Diagnostics, Inc. Corporate Intellectual Property-r338

20070281901 - Rnai-mediated inhibition of tumor necrosis factor alpha-related conditions: RNA interference is provided for inhibition of tumor necrosis factor α (TNFα) by silencing TNFα cell surface receptor TNF receptor-1 (TNFR1) mRNA expression, or by silencing TNFα converting enzyme (TACE/ADAM17) mRNA expression. Silencing such TNFα targets, in particular, is useful for treating patients having a TNFα-related condition or at risk... Agent: Winstead PC

20070281898 - Vector: The present invention relates to a retroviral vector system comprising a therapeutic gene wherein said retroviral vector system is pseudotyped with at least part of a heterologous envelope protein or a mutant, variant or homologue thereof and wherein said therapeutic gene is downstream of an internal promoter.... Agent: Frommer Lawrence & Haug

20070281902 - Adenosine a2b receptor agonists: wherein R1, R2, R3 and n have meaning as described in the specification, as adenosine A2B receptor agonists and, thus, may be employed for the treatment of diseases in mammals that are mediated by the A2B receptor including, but not limited to, septic shock, cystic fibrosis, impotence, diarrhea, and cardiac... Agent: King Pharmaceuticals, Inc.

20070281903 - Morinda citrifolia-based formulation 5-lox and 15-lox: The present invention is directed to methods and formulations for inhibiting Lipoxygenase enzymes that function to biosynthesize or metabolize arachidonic acid into its intermediate Leukotriene constituents, as well as a method and formulation for treating and preventing diseases, including inflammatory diseases, and the symptoms associated with such diseases. The present... Agent: Michael F. Krieger Kirton & Mcconkie

20070281905 - Use of simethicone in constipated patients: The invention relates to the use of simethicone for the preparation of a medication for the treatment of constipated persons suffering from bloated feeling during the night.... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20070281906 - Selective androgen receptor modulators for treating diabetes: This invention provides use of a SARM compound or a composition comprising the same in treating a variety of diseases or conditions in a subject, including, inter-alia, a diabetes disease, and/or disorder such as cardiovascular disease, atherosclerosis, cerebrovascular conditions, diabetic nephropathy, diabetic neuropathy and diabetic retinopathy.... Agent: Pearl Cohen Zedek Latzer, LLP

20070281908 - Composition and methods to treat cardiac diseases: Disclosed herein are N-methanocarba derivatives of AMP and their use in the treatment of cardiac and vascular diseases and conditions responsive to activation of the cardiac P2X receptor. In one embodiment, the N-methanocarba derivative of AMP is the N-methanocarba derivative of 2-chloro-AMP. Diseases and conditions responsive to activation of the... Agent: Cantor Colburn, LLP

20070281907 - Kinase inhibitor phosphonate conjugates: The invention is related to phosphorus substituted kinase inhibitory conjugates, compositions containing such conjugates, and therapeutic methods that include the administration of such conjugates, as well as to processes and intermediates useful for preparing such conjugates.... Agent: Viksnins Harris & Padys Pllp

20070281910 - Salicyl alcohol creatine phosphate prodrugs, compositions and uses thereof: Membrane permeable prodrugs of creatine phosphate, pharmaceutical compositions comprising membrane permeable prodrugs of creatine phosphate, and methods of treating diseases such as ischemia, heart failure, and neurodegenerative disorders comprising administering prodrugs of creatine phosphate or pharmaceutical compositions thereof are disclosed.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070281911 - Use of adefovir or tenofovir for inhibiting mmtv-like viruses involved in breast cancer and primary biliary cirrhosis: The active metabolites of adefovir and tenofovir (PMEApp and PMPApp) are active against the MMTV RT. They are 25-fold more potent than 3TCppp, suggesting that tenofovir and adefovir may be effective at inhibiting the MMTV-like retroviruses, which may be the etiological agents involved in PBC and breast cancer.... Agent: Gilead Sciences Inc

20070281913 - Method for treating eye disease or conditions affecting the posterior segment of the eye: Described is the use of prodrug for the manufacture of a medicament useful for treating an ocular disease affecting the posterior segment of the eye, in a subject in need thereof, wherein the prodrug is a composition injected into the vitreous body, and the frequency of injections does not exceed... Agent: Young & Thompson

20070281912 - Contraception method: A method of achieving contraception in a woman which comprises administering orally to said woman an estroprogestative composition comprising nomegestrol acetate and an estrogen is provided.... Agent: Cooper & Dunham, LLP

20070281914 - Use of a steroid prodrug for the treatment of disease of the posterior segment of the eye: Use of a composition comprising at least one prodrug of a steroid, preferably of a corticosteroid, for the preparation of an ophthalmic composition intended for the treatment of an ocular condition or disease of a human being or an animal.... Agent: Young & Thompson

20070281915 - Porphyrin derivatives and their use in photodynamic therapy: wherein X1, X2, X3, X4, Y1, Y2, Y3, Y4 and Z have meanings given in the description, and metallated forms of such compounds, which are useful in the treatment of medical conditions for which a photodynamic compound is indicated. Pharmaceutical formulations and methods of treatment of a medical condition for... Agent: Patrea L. Pabst Pabst Patent Group LLP

20070281916 - Substituted isoxazolines and their use as antibacterial agents: e

20070281917 - Hiv integrase inhibitors: The invention encompasses series bicyclic pyrimidinone compounds of Formula I which inhibit HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV.... Agent: Louis J. Wille Bristol-myers Squibb Company

20070281918 - Pyridoazepine derivatives: The present invention relates to pyridoazepine derivatives that act as 5-HT ligands, e.g., 5-HT2C ligands. The invention also relates to methods of preparing the compounds, compositions containing the compounds, and to methods of treatment using the compounds.... Agent: Forest Laboratories, Inc. Att: Michael Ciraolo

20070281920 - Benzazepine derivatives and uses thereof: e

20070281921 - Piperidinyl pyrimidine derivatives: wherein X, Y, Z, R1 and R2 are as defined in the description and claims. The compounds of the present invention act as antagonists and/or inverse agonists at the histamine 3 receptor and are useful for the treatment and/or prevention of diseases such as obesity, metabolic syndrome (syndrome X), and... Agent: Hoffmann-la Roche Inc. Patent Law Department

20070281922 - 1-sulfonylindazolylamine and - amide derivatives as 5-hydroxytryptamine-6 ligands: The present invention provides a compound of formula I and the use thereof for the treatment of a central nervous system disorder related to or affected by the 5-HT6 receptor.... Agent: Wyeth Patent Law Group

20070281919 - Aminothiazole derivatives and their use as crf receptor ligands: Substituted 4-phenyl-2-aminothiazole derivatives, processes for preparing the same, and the use thereof as corticotrophin releasing factor (CRF) antagonists.... Agent: Ross J. Oehler Sanofi-aventis U.s. LLC

20070281923 - Substituted pyridyl amide compounds as modulators of the histamine h3 receptor: Certain substituted pyridyl amide compounds are histamine H3 receptor modulators useful in the treatment of histamine H3 receptor-mediated diseases.... Agent: Philip S. Johnson Johnson & Johnson

20070281924 - Mif inhibitors for treating neuropathic pain and associated syndromes: Methods of using MIF inhibitors such as those characterized by structure I are disclosed. The MIF inhibitors can be used for treating conditions such as neuropathic pain and its associated symptoms, as well as for treating drug and behavioral addictions, such as opiate dependence. Additionally, MIF inhibitor compounds can be... Agent: Robins & Pasternak LLP

20070281925 - Use of sertindole for the preventive treatment of suicidal behaviour: The present invention relates to the use of sertindole in the preparation of a pharmaceutical composition for the preventive treatment of suicidal behaviour in human subjects suffering from a psychotic illness such as schizophrenia or schizoaffective psychosis.... Agent: Lundbeck Research Usa, Inc. Attention: Stephen G. Kalinchak, Legal

20070281926 - Rectal composition: A viscous or gellous pharmaceutical composition for the treatment of constipation by rectal administration comprises a polar lipid component, a polyvalent alcohol component, water, and optionally an oily triglyceride. Also disclosed is a compressible device filled with a single dose of the composition and a method for its manufacture; a... Agent: Dickstein Shapiro LLP

20070281927 - Anti-inflammatory and analgesic compositions and related methods: Methods and compositions for delivering a meloxicam compound are disclosed and described. In one aspect, a method may include perorally administering to a subject a therapeutically effective amount of a meloxicam compound that provides a meloxicam plasma concentration within 1 hour which is at least about 40% of the maximum... Agent: Thorpe North & Western, LLP.

20070281928 - Fused ring azadecalin glucocorticoid receptor modulators: The present invention provides a novel class of fused ring azadecalin compounds and methods of using the compounds as glucocorticoid receptor modulators.... Agent: Townsend And Townsend And Crew, LLP

20070281929 - Clathrate compound, method for controlling concentration of aqueous agricultural chemical active ingredient solution, and agricultural chemical formulation: The present invention provides a clathrate compound characterized by containing: a polymolecular host compound as a host compound; and an agricultural chemical active ingredient having a saturated solubility in water at 25° C. of not less than 500 ppm as a guest compound. The present invention also provides a method... Agent: Darby & Darby P.C.

20070281930 - Novel insecticides: and R8 is hydrogen; or an unsubstituted or substituted alkyl group; or forms, taken together with R5 or with a monovalent substituent attached to that atom of R7, via which atom R7 is directly connected with the carbon atom, shown in the formula I, which carries R8, one additional bond,... Agent: Syngenta Crop Protection , Inc. Patent And Trademark Department

20070281931 - Pharmaceutical composition containing a p2x7 receptor antagonist and methotrexate: The invention provides a pharmaceutical composition, pharmaceutical product or kit comprising a first active ingredient which is a P2X7 receptor antagonist, and a second active ingredient which is N-[4-[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-glutamic acid (methotrexate) or a pharmaceutically acceptable derivative thereof, for use in the treatment of inflammatory disorders.... Agent: Fish & Richardson P.C.

20070281932 - Method of preparing 4-halogenated quinoline intermediates: e

20070281933 - Novel indazole carboxamides and their use: wherein R1 and Z are defined below, and to pharmaceutically-acceptable salts thereof. The compounds of the invention are inhibitors of IKK2 and can be useful in the treatment of disorders associated with inappropriate IKK2 (also known as IKKβ) activity, such as rheumatoid arthritis, asthma, and COPD (chronic obstructive pulmonary disease).... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20070281934 - Indole derivatives as inhibitors of histone deacetylase: Described herein are compounds and pharmaceutical compositions containing such compounds, which inhibit the activity of histone deacetylase 8 (HDAC8). Also described herein are methods of using such HDAC8 inhibitors, alone and in combination with other compounds, for treating diseases or conditions that would benefit from inhibition of HDAC8 activity.... Agent: Wilson Sonsini Goodrich & Rosati

20070281935 - Use: an isomer thereof, a prodrug of said compound or isomer, or a pharmaceutically acceptable salt of said compound, isomer or prodrug, in the manufacture of a medicament for the palliative, prophylactic or curative treatment of negative energy balance in ruminants. The use of a compound of formula 1, in the... Agent: Pharmacia & Upjohn

20070281937 - Ion channel modulators: The invention relates to compounds, compositions comprising the compounds, and methods of using the compounds and compound compositions. The compounds, compositions, and methods described herein can be used for the therapeutic modulation of ion channel function, and treatment of disease and disease symptoms, particularly those mediated by certain calcium channel... Agent: Kirkpatrick & Lockhart Preston Gates Ellis LLP (formerly Kirkpatrick&lockhart Nicholson Graham)

20070281936 - Pyrimidine compounds as purine receptor antagonist: Compounds of formula (I); wherein R1 is H or NHZ; R2 is optionally substituted aryl or heteroaryl attached via a carbon atom; R3 is H; optionally substituted C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, or C3 C7 cycloalkyl, halogen; OH or OR, or R4 is H, optionally substituted C1-C6alkyl, C3 C6alkenyl, C3-C6alkynyl, C3-C7 cycloalkyl,... Agent: Banner & Witcoff, Ltd.

20070281938 - Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1: m

20070281939 - Benzamide inhibitors of the p2x7 receptor:

20070281940 - Uses of dpp-iv inhibitors: The specification describes the use of selected DPP IV inhibitors for the treatment of physiological functional disorders and for reducing the risk of the occurrence of such functional disorders in at-risk patient groups. In addition, the use of the above-mentioned DPP IV inhibitors in conjunction with other active substances is... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20070281941 - Amorphous form of a phosphoric acid salt of a dipeptidyl peptidase-iv inhibitor: The present invention relates to a novel amorphous form of the dihydrogenphosphate salt of (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine as well as a process for its preparation, pharmaceutical compositions containing this novel form, and methods of use of the novel form and pharmaceutical compositions for the treatment of diabetes, obesity, and high blood pressure.... Agent: Merck And Co., Inc

20070281942 - Glucokinase activators: e

20070281943 - Imidazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases:

20070281944 - Non-peptide bradykinin antagonists and pharmaceutical compositions therefrom: Disclosed are non-peptide compounds having activity as selective antagonists of bradykinin (BK) B2 receptor. The compounds are chemically characterized by the presence of an amino acid alpha substituted with a cyclic group and by a tetraalkylammonium group. Also disclosed are pharmaceutical compositions containing the compound, and methods of using the... Agent: Lerner, David, Littenberg, Krumholz & Mentlik

20070281945 - Benzoxazole and benzothiazole derivatives as 5-hydroxytryptamine-6 ligands: The present invention provides a compound of formula I and the use thereof for the treatment of a central nervous system disorder related to or affected by the 5-HT6 receptor.... Agent: Wyeth Patent Law Group

20070281946 - Tri(cyclo) substituted amide compounds: e

20070281947 - Diarylmethylpiperazines as prophylactic or therapeutic agents for viral myocarditis: To provide a prophylactic or therapeutic agent for viral myocarditis and viral myocarditis-related viral diseases by preventing or treating the occurrence of cell damage in various organs regardless of the type of virus. A prophylactic or therapeutic agent for viral myocarditis and via myocarditis-related via diseases is provided that comprises... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20070281948 - Substituted 2-pyridone derivatives, method for their preparation and their use as medicament: wherein R1 and R3 independently represent fluorine, methoxy, —OCF3, C2-C3-alkenyl or C1-C4-alkyl which is optionally substituted by chlorine, methoxy or one, two or three fluorine atoms; R2 represents hydrogen, fluorine, methoxy, —OCF3, C2-C3-alkenyl or C1-C4-alkyl which is optionally substituted by chlorine, methoxy or one, two or three fluorine atoms; X... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20070281949 - Substituted pyrazolopyrimidines: wherein R1, R2, R3, R4, R5, X, W, and ring A are as defined herein; pharmaceutical compositions of substituted heterobicyclic pyrimidines of Formula (I); and their use in the treatment of chronic neurodegenerative diseases, neurotraumatic diseases, depression and/or diabetes. More particularly, the present invention relates to substituted pyrazolopyrimidines of Formula... Agent: Cephalon, Inc.

20070281950 - Nitromethylene derivatives and their use: The present invention discloses nitromethylene derivatives and the uses thereof. These derivatives are obtained by adding ring structure onto the known nitromethylene compounds, by which both their stability for light and their liposolubility are increased. Furthermore, by using the substituents linked to ether bond, the steric orientation of the nitro... Agent: Dorsey & Whitney LLP Intellectual Property Department

20070281951 - Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors: In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20070281952 - Arylsulfonylnaphthalene derivatives as 5ht2a antagonists: Compounds of formula (I) are potent and selective 5-HT2A antagonists, useful in treatment of a variety of adverse conditions of the CNS.... Agent: Merck And Co., Inc

20070281953 - Substituted dihydroquinazolines ii: The invention relates to substituted dihydroquinazolines and to a method for the production thereof, the use thereof for treating and/or preventing diseases and for producing drugs for treating and/or preventing diseases, in particular for the use of the inventive dihydroquinazolines in the form of antiviral agents, in particular against cytomegaloviruses.... Agent: Jeffrey M. Greenman

20070281954 - Cyclohexyl-1,4-diamine compounds: e

20070281956 - Phenylpyrimidine amines as ige inhibitors: An amine, which is substituted by phenyl-substituted pyrimidin; and phenyl; and a third substituent and its use as an immunoglobulin E (IgE) inhibitor.... Agent: Novartis Corporate Intellectual Property

20070281955 - Raf inhibitors and their uses: The present invention provides imidazooxazole and imidazothiazole compounds and their synthesis. The compounds of the present invention are capable of inhibiting the activity of RAF kinase, such as B-RAFV600E. The compounds are useful for the treatment of cell proliferative disorders such as cancer.... Agent: Arnold & Porter LLP Attn:IPDocketing Dept.

20070281957 - Crystalline forms of levorphanol: The present invention relates to novel crystalline polymorphic forms of levorphanol including hydrated, solvated, and non-hydrated (non-solvated) forms. The invention also describes methods of preparing the various polymorphic forms. The present invention also relates to pharmaceutical compositions containing crystalline polymorphs of levorphanol, as well as methods of relieving pain by... Agent: Mallinckrodt Inc.

20070281958 - Preparation of oxycodone: A process for preparing oxycodone or an oxycodone salt, wherein the oxycodone or oxycodone salt has low levels of impurities (especially 14-hydroxycodeinone) is disclosed. The process comprises the steps of: a) preparing a mixture comprising oxycodone and a solvent and adjusting the pH of the mixture to less than 6;... Agent: Ratnerprestia

20070281959 - Glucocorticoid receptor modulator compounds and methods: p

20070281960 - Anti-histaminic composition: A stable pharmaceutical composition comprises desloratadine or a pharmaceutically acceptable salt, solvate, derivative, polymorph, hydrate or enantiomer thereof, and a carrier comprising at least one polyol. Preferred compositions comprise, in addition to desloratadine, from 50 to 80% polyol, from 5 to 15% disintegrating agent, and from 0.01 to 0.5% antioxidant... Agent: Conley Rose, P.C.

20070281961 - Modified compositions and methods for enhancing brain function: Compositions and methods are provided that enhance cognition in a human to which the composition is orally administered. Clinical studies have proven that contemplated compositions achieve specific improvements in cognition using a modified nootropic formulation having six active ingredients at or near threshold active dosages. Most preferably, the active ingredients... Agent: Fish & Associates, PC Robert D. Fish

20070281962 - Carboline derivatives useful in the inhibition of angiogenesis: In accordance with the present invention, compounds that inhibit the expression of VEGF post-transcriptionally have been identified, and methods for their use provided. In one aspect of the invention, compounds useful in the inhibition of VEGF production, in the inhibition of angiogenesis, and/or in the treatment of cancer, diabetic retinopathy... Agent: Arnold & Porter LLP Attn:IPDocketing Dept.

20070281963 - Pyrazoloquinolone derivative and use thereof: wherein R1 is an aryl group which may be substituted, or an aromatic heterocyclic group which may be substituted; R2 is a hydrogen atom, an amino group which may be substituted, a hydroxy group which may be substituted, or a thiol group which may be substituted; R3, R4, R5 and... Agent: Hamre, Schumann, Mueller & Larson, P.C.

20070281964 - Novel crystalline polymorphs of clopidogrel: The present invention relates to novel crystalline forms of the platelet aggregation inhibitor (+)-(S)-methyl-2-(2-chlorophenyl)-(6,7-dihydro-4H-thieno[3,2-c]pyrid-5-yl)acetate, clopidogrel (1), in the form of hydrogen bromide salts, identified as polymorph forms 1, 2 and 3. The present invention further relates to processes for preparing such forms, pharmaceutical compositions comprising such forms, and uses for... Agent: Wolf Greenfield & Sacks, P.C.

20070281965 - Preparation and utility of substituted imidazopyridine compounds with hypnotic effects: The present disclosure is directed to modulators of GABAA receptors and pharmaceutically acceptable salts and prodrugs thereof, the chemical synthesis thereof, and the medical use of such compounds for the treatment and/or management of sleep disorders and/or for providing a patient in need with a hypnotic, anxiolytic or anti-convulsive effect... Agent: Wilson Sonsini Goodrich & Rosati

20070281966 - Method for antagonizing mif activity: Methods of antagonizing MIF activity using ibudilast are described. Also described are methods of screening for MIF antagonists. These agents can be used for treating addictions, including drug and behavioral addictions, as well as for treating neuropathic pain.... Agent: Robins & Pasternak LLP

20070281968 - Compounds derived from artesunate, preparation process, pharmaceutical composition and use of the respective medicine: The present invention refers to new compounds derived from artesunate salts with quinolines represented by the general formula (I) where X is represented by the general formula (II) and Y is represented by the general formula (III) depending on the radicals substituted in X (formula II), the relation X to... Agent: Klarquist Sparkman, LLP

20070281969 - Niacin receptor agonists, compositions containing such compounds and methods of treatment: The present invention encompasses compounds of Formula (I); as well as pharmaceutically acceptable salts and hydrates thereof, that are useful for treating dyslipidemias. Pharmaceutical compositions and methods of use are also included.... Agent: Merck And Co., Inc

20070281967 - Nuclear transfer promoter for rac protein and method of screening the dame: A nuclear transfer promoter for Rac protein comprising an isoprenoid synthesis inhibitor and/or a geranylgeranyl transferase inhibitor such as an HMG-CoA synthase inhibitor, an HMG-CoA reductase inhibitor, an AMPK activator or a farnesyl pyrophosphoric acid synthase preparation; utilization thereof; a method therefor; a blood vessel remedy comprising the nuclear transfer... Agent: Westerman, Hattori, Daniels & Adrian, LLP

20070281971 - Novel compound: A succinic acid salt of biphenyl-2-ylcarbamic acid 1-[2-(2-chloro-4-{[(R)-2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethylamino]methyl}-5-methoxyphenylcarbamoyl)ethyl]piperidin-4-yl ester or a solvate thereof, for use in treating pulmonary disorders.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B475

20070281970 - Quinolinone-carboxamide compounds as 5-ht4 receptor agonists: The invention provides novel quinolinone-carboxamide 5-HT4 receptor agonist compounds of Formula (I). The invention also provides pharmaceutical compositions comprising such compounds, the use such compounds to treat diseases associated with 5-HT4 receptor activity, and processes and intermediates useful for preparing such compounds. Wherein; R1 is hydrogen, halo, hadroxy, C1-4 alkyl,... Agent: Theravance, Inc.

20070281972 - Pharmaceutical composition having prokinetic effect: The invention refers to the use of O-(3-piperidino-2-hydroxypropyl)nicotinic amidoxime or a pharmaceutically suitable acid addition salt thereof for the preparation of a pharmaceutical composition that restores and/or enhances the activity of the neuronal nitric oxide synthase enzyme.... Agent: Birch Stewart Kolasch & Birch

20070281973 - Sulphur containing pyrazole derivatives as selective cannabinoid cb1 receptor antagonists: e

20070281974 - 1 h-imidazole derivatives as cannabinoid receptor modulators:

20070281975 - Tartrate salt of isofagomine and methods of use: A novel tartaric acid salt of Isofagomine (Isofagomine tartrate) that can be used for the treatment of Gaucher disease is provided. The invention also provides a crystalline form of isofagomine tartrate, method for preparing the salt, a pharmaceutical composition containing the salt, and a method of treating Gaucher disease.... Agent: Baker Botts L.L.P.

20070281976 - Pesticidal agents on the basis of 1-aryl-aminopyrrol: Pesticidal Compounds The invention relates to 1-aryl-5-disubstituted-aminopyrrole derivatives of formula (I) or salts thereof: wherein the various symbols are as defined in the description, to processes for their preparation, to compositions thereof, and to their use for the control of pests (including arthropods and helminths).... Agent: Frommer Lawrence & Haug

20070281977 - Novel heterocyclic compounds: s

20070281978 - Inhibitors of aquaporin 4, methods and uses thereof: This invention relates an inhibitory modulator of AQP4 protein regarding its transmembrane water transport properties, wherein the modulator selectively binds to the AQP4 protein, and inhibits AQP4 mediated water transport.... Agent: Darby & Darby P.C.

20070281979 - New fbpase inhibitors for diabetes: i

20070281980 - Polymorphic forms of (s). -tetrahydrofuran-3-yl-3- (3- (3-methoxy-4- (oxazol-5-yl) pheny1) ureido) benzylcarbamate: The present invention relates to polymorphic forms of (S)-tetrahydrofuran-3-yl 3-(3-(3-methoxy-4-(oxazol-5-yl)phenyl)ureido)benzylcarbamate, processes therein, pharmaceutical compositions thereof, and uses therewith.... Agent: Vertex Pharmaceuticals Inc.

20070281981 - Therapeutic compounds: e

20070281982 - Process for purification of anastrozole: Anastrozole can be purified by crystallization from an aqueous-based solvent system. The aqueous-based solvent system can contain dilute acid, or an alcohol or both.... Agent: SynthonIPInc

20070281983 - Creatine analog prodrugs, compositions and uses thereof: Membrane permeable prodrugs of creatine analogs, pharmaceutical compositions comprising membrane permeable prodrugs of creatine analogs, and methods of treating diseases such as ischemia, heart failure, and neurodegenerative disorders comprising administering prodrugs of creatine analogs or pharmaceutical compositions thereof are disclosed.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070281984 - Use of metronidazole for preparing a pharmaceutical composition for treating a cutaneous inflammation: The invention relates to use of metronidazole for the preparation of a pharmaceutical composition for treating cutaneous inflammation, and preferentially the inflammatory component of rosacea.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20070281985 - Infusion fluid for dialysis patients: A pharmaceutical preparation including an amino acid infusion fluid is administered to patients receiving dialysis to ameliorate nutritional status of patients. As a result, anemia can be ameliorated and the required dose of erythropoietin can be reduced in these patients. Furthermore, the serum phosphate levels can be controlled to a... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20070281986 - Methods and compositions for modulating satiety: The present invention relates generally to a method for modulating the sensation of satiety perception and to agents useful for same. More particularly, the present invention identifies molecules which interact with ion channels thereby modulating the perception of satiety. The present invention contemplates, therefore, a method for modulating gastric distension... Agent: The Mccallum Law Firm, P. C.

20070281987 - N-phenylpyrazole derivatives as pesticides: The invention relates to polar 5-aminopyrazole carbamate derivatives of formula (I) or salts thereof: (I), wherein the various symbols are as defined in the description, to processes for their preparation, to compositions thereof, and to their use for the control of pests (including arthropods and helminths).... Agent: Frommer Lawrence & Haug

20070281988 - Combination therapy for vascular complications associated with hyperglycemia: The present invention relates to a method of treating one or more vascular complications of hyperglycemia comprising administering to a patient in need of treatment for one or more vascular complications to hyperglycemia a therapeutically effective amount of ruboxistaurin, or a pharmaceutically acceptable salt thereof in combination with a therapeutically... Agent: Eli Lilly & Company

20070281989 - Process for preparing duloxetine and intermediates thereof: Processes for preparing chemically pure duloxetine and chemically pure duloxetine intermediates are provided.... Agent: Kenyon & Kenyon LLP

20070281990 - Methods of using low-dose doxepin for the improvement of sleep: Methods of preventing early awakenings, and improving sleep efficiency in hours 7 and 8 of a period of sleep, by administration of low doses of doxepin (e.g., 1-6 mg).... Agent: Knobbe Martens Olson & Bear LLP

20070281992 - Combination of gyrase b inhibitors and protein synthesis inhibitors and uses thereof: The present invention relates to compounds and methods of treating, preventing, or lessening the severity of drug-resistant Gram-positive bacterial infections in mammals. The compounds consist of a combination of a gyrase B inhibitor and a protein synthesis inhibitor. These compounds demonstrate antibacterial activity against drug-resistant strains of Gram-positive bacteria, and... Agent: Price Heneveld Cooper Dewitt & Litton, LLP

20070281991 - Preparation of phenol-amide compounds with anti-oxidizing properties: The invention relates to the preparation of compounds comprising at least one phenol function and one amide function derived from amino-2-alkanol-1 having formula (I) and (II), which have antioxidant and an tiradical properties and which are soluble in lipid media. The inventive compounds can be used as cosmetic or pharmaceutical... Agent: Patent Docket Administrator Lowenstein Sandler PC

20070281993 - Structured triglycerides and emulsions comprising same: The present invention relates to structured triglyceride, to parental nutrition emulsions comprising same, and use thereof. In particular, the invention relates to structured triglycerides comprising at least one medium chain C6-C12 fatty acid and at least one fatty acid selected from the group consisting of long chain C14-C18 or very... Agent: Winston & Strawn LLP Patent Department

20070281994 - Use of furan alkyls for a cellulite cosmetic treatment: The invention relates to the use of one or several synthetic or natural furan alkyls for cosmetically treating cellulite. Said furan alkyls preferably correspond to formula (I), wherein identical or different R1, R2, R3 et R4 are independently of each other a hydrogen atom, a C1-C35alkyl radical, C1-C35 alcenyl radical... Agent: Foley And Lardner LLP Suite 500

20070281995 - Creatine analog prodrugs, compositions and uses thereof: Membrane permeable prodrugs of creatine analogs, pharmaceutical compositions comprising membrane permeable prodrugs of creatine analogs, and methods of treating diseases such as ischemia, heart failure, and neurodegenerative disorders comprising administering prodrugs of creatine analogs or pharmaceutical compositions thereof are disclosed.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070281996 - Creatine prodrugs, compositions and uses thereof: Membrane permeable prodrugs of creatine, pharmaceutical compositions comprising membrane permeable prodrugs of creatine, and methods of treating diseases such as ischemia, heart failure, and neurodegenerative disorders comprising administering prodrugs of creatine or pharmaceutical compositions thereof are disclosed.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070281998 - Treatment of hot flashes using muscarinic receptor antagonists: The present invention relates to a method of treating hot flashes by administering a muscarinic receptor antagonist. The method is useful for treating peri- and post-menopausal women, including women who have undergone surgically induced menopause.... Agent: Philip S. Johnson Johnson & Johnson

20070281997 - Treatment of hot flashes using muscarinic receptor antagonists: The present invention relates to a method of treating hot flashes by administering a muscarinic receptor antagonist. The method is useful for treating men with prostate disorders being managed with androgen deprivation therapy.... Agent: Philip S. Johnson Johnson & Johnson

20070281999 - Alcohol-containing antimicrobial compositions having improved efficacy: Antimicrobial compositions having a rapid antiviral and antibacterial effectiveness, and a persistent antiviral effectiveness, are disclosed. The antimicrobial compositions contain (a) a disinfecting alcohol, (b) a blend containing a C12 to C22 alcohol and an ethoxylated C12 to C22 alcohol, such as a cetearyl alcohol and cetereth-20 blend, a cetearyl... Agent: Marshall, Gerstein & Borun LLP (dial)

20070282000 - Triacylglycerol-based alternative to paraffin wax: A triacylglycerol-based wax, which can be used in candle making, is provided. The triacylglycerol-based material is predominantly includes a triacylglycerol stock which has a fatty acid profile has no more than about 25 wt. % fatty acids having less than 18 carbon atoms. In addition, the fatty acid profile of... Agent: Cargill, Incorporated

20070282002 - Acylamide compounds having secretagogue or inducer activity of adiponectin: The present invention provides an acylamide compound of the following formula (1), prodrugs thereof, or pharmaceutically acceptable salts thereof; and an adiponectin inducer or secretagogue, therapeutic agent of metabolic syndromes, therapeutic agent of hypoadiponectinemia, therapeutic agent of hyperlipemia, preventive/therapeutic agent of diabetes, improving agent of impaired glucose tolerance, improving agent... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20070282001 - Materials and methods for improving shellfish health, immunity and growth: The subject invention provides methods for improving shellfish health. In specific embodiments, the invention provides methods for accelerating and/or augmenting shellfish growth; improving immunity; and enhancing fertility in shellfish. To do so, the present invention provides materials and methods for administering a cysteamine compound to shellfish.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20070282003 - Compounds for the treatment of metabolic disorders: Agents useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis are disclosed. Formula (I), wherein n is 1 or 2; m is 0 or 1; q is 0 or 1; t is 0 or 1; R5... Agent: Lewis J Kreisler Legal Department

20070282004 - Use of a cyclopentenone prostaglandin for delaying for the onset and/or preventing the continuation of labour: The present invention provides the use of a cyclopentenone prostaglandin in the manufacture of a medicament for delaying the onset and/or preventing the continuation of labour in a female. Preferably the cyclopentenone prostaglandin prevents and/or reduces an inflammatory response in the reproductive system of a female. Preferably, the cyclopentenone prostaglandin... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20070282005 - Hmgb1 expression and protective role of semapimod in nec: Methods are described, which include the administration of semapimod or guanylhydrazone containing compounds, salt thereof, or a combination of the compound and a salt thereof for the inhibition, treatment, and/or prevention of any of NEC, a condition associated with the release of HMGB1, a condition associated with the release of... Agent: Dla Piper US LLP Attn: Patent Group

20070282006 - Method of enhancing hair growth: wherein the dashed bonds represent a single or double bond which can be in the cis or trans configuration, A, B, Z, X, R1 and R2 are as defined in the specification. Such compositions are used in treating the skin or scalp of a human or non-human animal. Bimatoprost is... Agent: Robert J. Baran (t2-7h) Allergan, Inc.

20070282007 - Treatment of pain disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine and its formamide: Treatment of pain disorders with (1R,4S)-trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine; and (1S,4R)-trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine is disclosed. A process for preparing 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine is also disclosed. The process includes the preparation of all four isomers of N-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide, which are also useful in treatment of pain disorders.... Agent: Heslin Rothenberg Farley & Mesiti PC

20070282008 - Antimicrobial compositions and methods for their use: Topical and wash compositions comprising a polymeric biguanide or a bis(biguanide) compound, a chelating agent and a buffering agent and methods for using these compositions for the prevention or treatment of skin or ear tissue infections is provided.... Agent: Welsh & Katz, Ltd

20070282009 - Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors: A pharmaceutical composition comprises a solid amorphous dispersion of a cholesteryl ester transfer protein inhibitor and a concentration-enhancing polymer.... Agent: Pfizer Inc.

20070282010 - Methods of accelerating muscle growth, decreasing fat deposits and improving feed efficiency in livestock animals: A method of promoting or improving the feed efficiency and the muscle to fat ratio in animals by administering to the animals a therapeutically effective amount of a pure or substantially pure RR-isomer of ractopamine is disclosed. Also disclosed are animal feed preparations and compositions and pharmaceutical preparations capable of... Agent: Viksnins Harris & Padys Pllp

20070282011 - Biodegradable water soluble polymers: The invention provides biodegradable, water soluble PEA, PEUR and PEU carrier polymers, which can be used to conjugate, and thereby stabilize and/or solubilize, bioactive agents via polar uncharged or charged groups and activated ester or amino groups contained in the building blocks that make up the backbone of the polymer.... Agent: Dla Piper US LLP

20070282012 - Reagent for lacrimation examination and method of lacrimation examination: e

20070282013 - Pharmaceutical compositions comprising peranhydrocyclodextrin: The present invention relates to a pharmaceutical composition comprising a peranhydrocyclodextrin a drug and a carrier, to the use of a peranhydrocyclodextrin as a drug transport enhancer (e.g. permeation enhancer), and to the use of a peranhydrocyclodextrin in the preparation of a pharmaceutical composition as a synergistic adjunctive system.... Agent: Novartis Corporate Intellectual Property

20070282014 - Hydroxyethylstarch: Described are a hydroxyethylstarch, a process for the preparation thereof, a pharmaceutical formulation containing such a hydroxyethylstarch, and the use of the pharmaceutical formulation for the preparation of a volume replacement, a plasma replacement or a plasma volume expander, as well as the use of the pharmaceutical formulation for maintaining... Agent: Christie, Parker & Hale, LLP

20070282017 - Methods and compositions for treating and preventing neurologic disorders: The present invention provides methods for treating or reducing neurologic disorders.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.C.

20070282016 - Methods and compositions for use of angiogenesis inhibitors in the prevention and/or control of epilepsy: In accordance with some preferred embodiments, without limitation, the invention comprises methods and compositions for the prophylactic and/or antiepileptic administration of angiogenesis inhibitors in conjunction with seizures or traumatic insults to the brain, which administration may limit the extent of trauma-associated angiogenesis and/or decrease the likelihood that angiogenesis will give... Agent: Rader, Fishman & Grauer PLLC

20070282015 - Novel splice variants of human dkkl1: The present invention relates to novel sequences for use in detection, diagnosis and treatment of diseases, including cancer. The invention provides novel splice forms of human DKKL 1 gene. The present invention provides methods of using polynucleotides having the novel splice variants of the human DKKL 1 sequences, their corresponding... Agent: Novartis Vaccines And Diagnostics Inc.